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MULTIPLEXED CRISPR LIBRARIES FOR CANCER FUNCTIONAL
GENOMICS
Jintan Liu, Bachelor of Science
Advisory Professor: Giulio F. Draetta, M.D., Ph.D.
High-throughput forward genetic screenings are invaluable tools to
systematically explore genetic interactions and to link gene disruption with disease
contexts. The adaptation of CRISPR/Cas9 has improved the sensitivity and specificity
of functional screenings. Despite this advance, there remains a long-standing need to
improve functional screenings with smaller and more versatile pooled libraries.
Capitalizing on the inherent multiplexing capability of a class 2 CRISPR enzyme
AsCpf1, we developed a multiplexed, high throughput screening strategy that has
avoided the usual trade-off between library size and library penetration, allowing library
minimization without sacrificing gene targeting efficiency. We optimized the AsCpf1
protein for functional genomics use and demonstrated that an AsCpf1-based
multiplexed library outperforms its monocistronic CRISPR/Cas9 library counterpart with
a greatly reduced library size. With this strategy, we constructed the smallest wholegenome CRISPR knock-out library, Mini-human, for the human genome (n=17,032
constructs targeting 16,977 protein-coding genes), which performs favorably compared
to conventional Cas9 libraries.
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Chapter 1: Introduction
Part of this chapter is based on the article titled Pooled library screening with
multiplexed Cpf1 library (Liu J, Srinivasan S, Li C-Y, Ho I-L, Rose J, Shaheen M, Wang
G, Yao W, Deem A, Bristow C, Hart T, Draetta G. Pooled library screening with
multiplexed Cpf1 library. Nat Commun. 2019;10:3144.) was published in Nature
Communications in 2019. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY 4.0). Under Creative Commons,
authors retain copyright in their articles and I am the primary author of this article. I am
the first author of this article.
1.1

Pooled functional genomics screenings in cancer drug target discovery
Technologies such as the microarray and next-generation sequencing offer an

efficient way to decode mechanisms of cancer in a “phenotype-to-gene” direction.
Functional reverse genetics screening, which goes in a “gene-to-phenotype” direction,
serves as a complementary strategy to dissect regulatory networks and identify novel
genes in cancer studies. Pooled library-based genomic reverse screening in
combination with next-generation sequencing analysis combines the advantages of
forward genetics and reverse genetics. In a pooled library, different constructs,
including complementary DNAs (cDNAs)[1], microRNAs[2], small hairpin RNA
(shRNAs) [3], or Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR)/Cas9 based guide RNAs (gRNAs) [4] are mixed together and become one
population. The vector of the construct can be virus-based such as lentivirus, adeno1

associated virus(AAV) [5] and plasmids[6] depending on different research topics. This
is different from the array-based libraries where constructs are separated individually
and can be picked out if desired. In a pooled library-based screen, cells are treated
with the pooled constructs, consisting of one large heterogeneous population.
Historically, Kemp et al. first introduced the pooled library method[7]. Pooled library
based screening strategies offer a cost-effective and less labor-intensive method to
investigate multiple genes of interest systematically. Especially when doing an in vivo
screening in mouse models, the advantage of pooled library screening is
unprecedented, given that thousands of genes can be tested simultaneously in a very
limited number of cohort.
In contrast to array-based high throughput screening, in pooled library-based
screening, constructs are not individually tractable. In an ideal pooled library, constructs
are equally distributed. However, in reality, constructs in the library are usually normally
distributed. The variance of construct abundance distribution should be as small as
possible[8]. The dynamic range of most constructs is usually within around 10 fold or
less variation[4],[9],[10],[11].
In a pooled library screening, the cell population is constantly subjected to
random effects, independent of the added selection pressure even with sufficient library
coverage. Because of the founder effect, loss of representation in any step will lead to
seriously skewed screening outcomes[12]. The impact of the founder effect is more
profound in negative screening. In a negative screening, the interested hits genes are
those that are depleted after the screening. Genes depleted randomly will “drop out” as
false positive hits if the library is not fully represented. Generally, coverage should be
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as deep as possible to prevent the effects of genetic drift in a cell population. As a
reference, here we provide a summary of coverage used in existing libraries.
Pooled library
type
cDNA
cDNA
cDNA
cDNA
cDNA
cDNA(miRNA)
RNAi
RNAi
RNAi
RNAi

In vivo or in
vitro
in vivo
in vitro
in vitro
in vivo
in vitro
in vitro
in vivo
in vitro
in vitro
in vitro/in
vivo

Coverage used

Type of screening

Reference

~100000
~200
N.A
N.A
~1000
N.A
>1000
~1000
~985
∼4,500 in
vitro, >90,000
in vivo
N.A
~270
for negative
screening,
~370 for
positive
screening
~300
>400

positive
positive
positive
positive
Positive
positive
negative
negative
negative
negative

[13]
[14]
[1]
[5]
[15]
[2]
[16]
[17]
[18]
[19]

RNAi
RNAi/Cas9

in vivo
in vitro

negative
positive/negative

[20]
[21]

Cas9
Cas9
Cas9
Cas9
Cas9
Cas9
Cas9a

in vitro
in vitro/in
vivo
in vitro
in vitro
in vitro
in vitro
in vitro

positive/negative
positive

[9]
[22]

~68 /~113
>500
~400
~1000
>500

positive
negative
positive/negative
positive
positive

[4]
[23]
[10]
[11]
[24]

Cas9i

in vitro

>1000

positive

[25]

Cas9i/Cas9a

in vitro

>3750

negative

[25]

Table 1 Summary of coverage used in pooled library screenings
1.2

CRISPR/(Sp)Cas9
Clustered Regularly Interspaced Short Palindromic Repeats is found in bacterial

adaptive immune system[26]. In bacteria, upon phage infection, class 2 CRISPR
system recognizes and actively eliminates a recognized phage DNA. CRISPR
3

associated protein 9 (Cas9) is a DNA endonuclease, which is able to introduce DNA
double-strand break at a specific genome location with the guidance of the transactivating crRNA (tracrRNA) and CRISPR RNA (crRNA) complex. The most widely
used CRISPR/Cas9 system is simplified from bacteria Streptococcus pyogenes,
consisting of Cas9 (SpCas9) and a tracrRNA - crRNA complex chimera – the so-called
single guide RNA(sgRNA) [27]. The Cas9/sgRNA complex recognizes a 20 bp
customizable DNA target sites which is defined by the sequence of a 20 bp
protospacer, followed by a “5’-NGG-3’” [27], “5’-NAG-3’”, or “5’-NGA-3’” [28] adjacent
motifs (PAM) and introduces a blunt end double-strand DNA break 3 bp upstream of
PAM.
The double-strand DNA breaks introduced by CRISPR systems lead to cell
death in prokaryotic cells while mammalian cells usually tolerate double-strand DNA
breaks well. Depending on how the DNA breaks are repaired in the mammalian cells,
knock-out or knock-in of a gene is possible. Knock-out of a gene is usually a
consequence of the activation of the non-homologous end joining (NHEJ) DNA repair
machinery. Targeted genes in mammalian cells can be inactivated by premature stop
codon or frameshift mutations because NHEJ is more error-prone compared with other
DNA repair machinery and often introduce mutations after repair. Cas9 has two
independent DNA cleavage sites for each strand of DNA. They can be inactivated
individually by introducing point mutation D10A or D840A and still retains its precise
DNA binding activity. Single site inactivated Cas9 mutants can be adopted as an off-set
Cas9 nickase[29],[30]. Cas9 nickase works in pairs and introduces double-strand
breaks only when two nickases bind to two adjacent (<100bp ) loci in two different
strand orientations. Therefore, it is a more precise DNA modification tool compared
4

with wild type Cas9. Double sites inactivated Cas9(dCas9) is catalytic dead and cannot
introduce DNA double-strand breaks but retains its specific DNA binding activity. By
fusing it to other functional domains such as epigenetic modifiers, site-specific gene
modifications can be achieved such as epigenetic silencing (CRISPRi) and
transcriptional activation (CRISPRa) [25]. CRISPRi works by fusing dCas9 with
epigenetic silencer such as KRAB[31], even though dCas9 alone is sufficient to
suppress targeted gene expression, while CRISPRa is achieved by fusing dCas9 with
transcriptional activators like VP64 and VP64-p65-Rta (VPR) [31].
The most obvious advantage of CRISPR/Cas9 mediated gene knock-out is the
permanent DNA modification. However, complete knock out of certain genes might
result in different cellular response compared with gene knockdown. Complete
depletion of egfl7 using CRISPR/Cas9 has no obvious phenotype while partial
knockdown of egfl7 results in severe vascular defects in zebrafishes. This is partially
because complete depletion of egfl7 activates compensatory pathways due to robust
genetic regulatory networks [32]. In another study, RAF1 cannot be validated as a
human lung cancer target using an RNAi based approach. Complete depletion of RAF1
gene by CRISPR/Cas9, however, demonstrated that RAF1 is essential for KRAS
mutant cancer cells proliferation[33]. Cas9 is well known for its much better precision
compared with RNAi. However, it also has off-target effects. It has a 10-12 bp seed
region in adjacent with PAM where mismatches are less likely to be tolerated[29],[34].
This is slightly longer than shRNA’s seed region. It is also reported truncation of 20 bp
guide sequence down to 17bp reduces its off-target effects [29],[35].
1.3

CRISPR/Cas12a(Cpf1)
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Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and
Francisella (CRISPR/Cpf1) or CRISPR/Cas12a is another member of the class 2
CRISPR system[36]. Different from type II CRISPR-Cas system Cas9, Cpf1 is type
V[36],[37] and is also capable of inducing phage DNA cleavage with a CRISPR
associated protein Cpf1 (or Cas12a) and its editable RNA ligand crRNA. Even though
Cpf1 have a 26~30bp length of protospacer in its native hosts. It was found that only
the first 20 bp is required to cleavage its target[38]. Truncating the protospacer to 15bp
leads to compromised Cpf1 DNA cleavage activity but does not abrogate its efficient
binding activity[39]. Unlike Cas9’s RNA ligand which is a dual-RNA complex consisting
of tracrRNA and crRNA, Cpf1’s crRNA is self-sufficient to guide its binding protein to
the DNA target and it is much smaller than Cas9’s single guide RNA (40bp vs 104bp)
[36]. Cpf1 requires a 5’ “TTTV” PAM in order to recognize all possible DNA targets[40].
After successful target recognition, it introduces a staggering dsDNA break albeit with a
slower cutting kinetic compared with Cas9[41]. The staggered dsDNA break generates
a 5’ overhang and is considered the reason why the mutation pattern introduced by
Cpf1 is predominantly small deletions rather than small insertion and deletions
compared with Cas9. CRISPR-Cpf1 is considered as a more concise CRISPR system
compared with CRISPR-Cas9. Cpf1 only has one DNA cleavage motif while Cas9 has
two[42]. In the CRISPR system, different crRNAs are interspaced by repetitive DNA
sequences and requires Cas proteins to process their multi-cistronic transcript into
individual mature crRNA. Cpf1 is self-sufficient for this process, unlike Cas9, which
requires other Cas proteins and RNase III to process polycistronic guide precursors in
its native host[43]. It has been demonstrated that the Cpf1 orthologues LbCpf1 and
AsCpf1 are highly specific, comparable or greater than SpCas9[38], [44]. Similar to
6

Cas9, CRISPRi or CRISPRa is also viable for Cpf1 by fusing catalytically dead Cpf1
(dCpf1) protein to function domains.
Cpf1 has been shown to induce or suppress gene expression when fused with other
functional domains [45-47], and there are reports of a strong, on-target synergistic
effect of multiplexed Cpf1-based CRISPRi and CRISPRa strategies[48].

1.4

CRISPR/Cas9 based pooled library screenings
CRISPR/Cas9 system has been demonstrated to be powerful in both positive

and negative pooled library screenings in cancer research with various Cas9 formatregardless of whether it is wild type Cas9 or Cas9 fusion proteins with modified
functions. As an example using Cas9 for negative screenings Wang et al. performed a
genome-wide screening with a chronic myeloid leukemia cell line KBM7[10]. KBM7 cell
line is near haploid, which is efficient for genome editing for its ploidy. In the large
negative screening they conducted, they adopted both HL60 and KBM7 cell lines. Both
of them showed strong depletions in essential genes such as ribosomal protein genes,
genes related to DNA replication, transcription and protein degradation, albeit the
pseudo-haploid cell line KBM7 gives a better result. CRISPR system can also be used
for positive screenings. To explore genes responsible for vemurafenib sensitivity,
Shalem et al. conducted a screening in BRAFV600E carrying melanoma cell line
A375[21]. In this screening, previously identified genes such as NF1 and MED12 was
also identified, along with unidentified genes such as NF2, CUL3, TADA, and TADA2B.
Strikingly, compared with previously conducted shRNA-based screening,
CRISPR/Cas9 based screening showed a shaper cut between hits and non-hits.
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Essential genes for vemurafenib sensitivity also showed better enrichment in
CRISPR/Cas9 based one.
dCas9 fusion proteins can also be employed in the pool library screening. By
adopting dCas9-VP64 fusion protein, Konermann S. et. al. showed that transcriptional
activation screening is possible. In this pooled library screening, A375 cells harboring
different sgRNAs were selected against vemurafenib progenitor PLX-4720 resistant.
Overexpression of all 13 top hits individually conferred similar results. Among all of the
top hits, 5 hits are also identified in previous cDNA based screening, indicating
comparable results. [24] Bastiaan E. also demonstrated CRISPRi could be used for
pooled library screen.

1.5

Guide design for (Sp)Cas9 based pooled libraries
Guides of Cas9 plays a critical role in Cas9 based genome engineering. They

have pronounced effects in determining Cas9’s gene targeting efficacy and precision.
CRISPR/Cas9 shows distinct gene inactivating pattern compared with RNAi[21].
Depending on the guide’s efficiency and exposure time to its target, it can generate a
complete knockout homozygote, a partially knock out clone (heterozygote) and in the
worst case, wild type homozygote when its efficiency is zero. Therefore, the expression
pattern of its target gene is consists of one or several peaks after the introduction of the
CRISPR system, while the pattern of RNAi is one narrow or broad spectrum depending
on different RNAi efficacy. This also indicates that CRISPR/Cas9 and RNAi based
gene inactivation have different levels of penetrance. Despite its high throughput
advantage, pooled library screen suffers from decreased sensitivity and accuracy
compared with low throughput individual validation of a set of genes. It is essential to
8

have highly efficient and precise guides in a pooled Cas9 based library to have high
signal-to-noise ratio. Wild type Cas9 that has dsDNA cleavage activity that is largely
dependent on NHEJ to inactivate genes after a dsDNA break is introduced. Compared
with RNAi based approach that results in transcript degradation regardless of where
the target regions are, the target regions of CRISPR/Cas9 are often preferred at the
beginning of coding sequence. However, this sometimes also yields in-frame mutants
that are still functional, offsetting gene knockout efficacy. Targeting function domains of
interested genes generate higher penetrance and substantially optimizes negative
screening. Reported by Shi j et.al, by using this method, they identified 6 known drug
targets and 19 additional dependencies in murine acute leukemia cells in a pooled
CRISPR/Cas9 based library targeting 192 chromatin regulatory domains[23]. For
CRISPRi and CRISPRa, the optimal targeting locations for the guides are different from
Cas9 knockouts. Both CRISPRi and CRISPRa benefit from guides that are close to
transcription start sites. CRISPRi’s guide performs best from 25 to 75nt downstream of
the transcription start site while CRISPRa’s is optimal when it targets from 75-150nt
upstream of the transcription start site.
The nucleotide component of guides is predictive of their gene targeting
efficiency. “On-target” predicting algorithms for Cas9 based guides are well defined by
utilizing functional genomics screening data comprising thousands of guides targeting
genes that have well-characterized phenotype when they are knocked out. The genes
chosen were either cell survival and proliferation essential genes [49] or surface
proteins that could be examined by flow cytometry[50]. Different analysis method were
used to generate the “on-target” rules. However, they shared the same concept
pioneered by Wang et.al by analyzing the sequence features of guides that produce
9

expected phenotypes after gene knock out[10]. The most widely used Cas9 guide
predicting algorithm was developed by Doench et.al, which utilized a combined dataset
comprising over 4,000 guides targeting 17 different genes[51]. The development of “ontarget” predicting algorithms improved Cas9 based pooled CRISPR libraries with more
compacted size and higher efficiency.
1.6

Deconvolution and analysis of pooled CRISPR library screenings
After the pooled library screen experiment is done, the next step is to

deconvolute the abundance changes of gene targeting guides. Historically, the
customized microarray is used for high throughput quantification of shRNA abundance
when the next generation sequencing (NGS) technology was not available and the
pooled library screenings were limited to shRNA-based libraries. However, NGS quickly
outcompeted microarray when it was available and became the standard method of
deconvolution when the first pooled CRISPR library came out in 2013, because of its
higher signal-to-noise ratio and much richer information. In a pooled CRISPR library,
one gene is usually targeted by multiple guides to maximize the possibility that there is
one functional guide. However, this became a problem when the screening data were
deconvoluted: “how to capture the true signals from a mixture of functional and nonfunctional guides targeting the same gene?” Different methods were developed in order
to address this question. RNAseq and RNAi based library screening analysis pipelines
such as DESeq2[52] and RIGER[53] were used in the early development of CRISPR
based library screening. More sensitive and robust methods such as MAGeCK[54] and
BAGEL[55] were developed later based on different mathematical models where
MAGeCK is based on a robust ranking aggregation of guides and BAGEL is based on
likelihood calculation between two training gene sets. It is now generally accepted that
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copy number related fitness drop upon gene knockout should be considering in the hits
call analysis of Cas9 knock out library screenings[56,57]. First reported by Hart et.al,
Cas9 based knock out method was found highly cytotoxic when highly amplified genes
were knocked out[58]. This toxicity was independent of the function of the knocked-out
genes and was considered caused by excessive dsDNA breaks introduced by Cas9.
The copy number related cytotoxicity decreased the signal-to-noise ratio of knock out
screenings and an algorithm called CERES has been developed to address it. [59]
1.7

Currently available pooled genome-wide CRISPR libraries and challenges
of pooled library screenings
All pooled CRISPR libraries available to the research community today were

based on the CRISPR-Cas9 system and the majority of them were lentivirus-based and
designed for human and mouse genomes. The only two non-mammalian genome-wide
pooled CRPSR libraries available are for fruit fly and for protozoan parasite
toxoplasma. Both libraries are plasmid-based. The fruit fly library consists of ~40,000
guides targeting 13,501 genes, with most genes having 3 guides[9]. The toxoplasma
library contains ten guides against 8,158 genes[6]. It is not virus based and can be
directly transfected into the parasite. All types of Cas9 based gene interfering methods
including knockout, CRISPRi, and CRISPRa are available for the mouse and human
genome-wide libraries. Depending on whether the activity of guide is computationally
optimized or not, 70,000~190,000 vectors are designed for each library, with 4~10
guides designed for each gene. The first unoptimized genome-wide libraries were
released by Feng Zhang’s group, with 3-4 guides designed for each gene[21]. After
identification of Cas9’s guide preference rules, different genome-wide optimized pooled
libraries were released. For CRISPR knock out human libraries, Brunello[60],
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TKOv3[61], and Wang[10] libraries are optimized, with a library size of ~70,000 for
Brunello and TKOv3, and ~190,000 for Wang. For the mouse counterparts, Brie is the
optimized one with ~80,000 guides. For CRISPRi human libraries, Dolcetto[62] and
CRISPRi-v2 [63]are optimized, with a size of ~110,000 and ~210,000 respectively. For
the mouse counterparts, Dolomiti[62] and CRISPRi-v2(mouse) are optimized. Dolomiti
has a size of ~130,000 and CRISPRi-v2(mouse) is ~210,000. Similar optimized
CRISPRa human and mouse libraries are available. Calabrese(human) [62] and
Caprano(mouse) [62] have a similar size of Dolcetto. CRISPRa-v2 [63] (human and
mouse respectively) have a similar size of CRISPRi-v2. These optimized libraries have
greatly increased our ability to dissect genetic interactions in a disease-relevant
context.
However, challenges still exist for all of these current libraries. Like pooled
shRNA screens, pooled sgRNA screens benefit from multiple constructs targeting each
gene of interest, as the functionality of each construct is largely unknown. However,
increasing the number of genetic reagents per target to improve the efficacy of the
library comes at the expense of increasing library complexity, which in turn increases
labor requirements as well as costs for reagents and sequencing. Because inactive
constructs cannot be physically removed from the library, they serve as confounding
factors during hit identification. While this can be partially mitigated with hits
identification algorithms such as MAGeCK[54] and BAGEL[55,56], there remains a
need to further enhance CRISPR technology to improve library penetrance with
smaller, more versatile pooled libraries. Several algorithms have been developed to aid
in the design of sgRNAs with high-efficiency guides[51,61,64,65] to minimize the
number of constructs needed to yield robust results, but there remains a need for
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additional advancements to vastly decrease library size especially in the settings of
scale-limited experiments, such as in vivo functional genomics screenings.
1.8

Cas9 based multiplexed genome editing and its limitations in functional
genomics screenings
All of the previously discussed CRISPR libraries share an identical configuration

of guides in their vectors: Only one guide is expressed from one vector. CRISPR/Cas9
system in the native host, however, is multicistronic and is capable of editing different
targets in a multiplexed format. This can be reconstituted in mammalian cells in a low
throughput manner. Since Cas9 does not have guide-processing activities like Cpf1,
each promoter can only have one sgRNA expressed. Historically, chromosomal-level
large fragment deletion has been demonstrated viable in human cells by cotransfecting multiple plasmids targeting different loci. Two strategies were generated to
reconstitute the multiplexing genome editing property of Cas9 from one vector in
mammalian cells. The first strategy is to use multiple promoters to drive the expression
of multiple guides. Gersbach’s group demonstrated up to 4 guides expressing cassette
can be multiplexed in one lentiviral vector in 2014[66]. Later, functional genomics
screening utilizing paired guide expression has been proved viable for lncRNAs[67].
Another strategy for multiplexed genome editing is to reconstitute the guide processing
by the aid of other systems. Different DNA sequences have been tested whether they
can aid in the processing of multicistronic transcript when they are inserted between
guides. They are able to induce site-specific cleavage in the aid of helper RNases such
as RNase P and RNase Z when tRNA is inserted[68], and Cas6/Csy4[69] when its
recognition sequence is inserted. Ribozymes[70] was also tested because they are cisacting RNA cleavage elements.
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Despite all of the effort, Cas9’s utility of multiplexed genome editing in pooled
function genomics screenings is quite limited. One of the drawbacks for Cas9 based
multiplexed genome editing is the long scaffold sequence and long repetitive elements
between each guide or guide expressing cassette. They result in vector recombination
and template shuffling[71],[72] which significantly cripple their utility in functional
genomics screens, where most data are acquired using short-read next generation
sequencing. Methods of high throughput examining gene-to-gene functional
interactions have always been a great interest in system biology field and
pharmaceutical companies because they can lead to the fast characterization of signal
networks and new drug development, for example, novel drug combinations and
synthetic lethal drug target identification in cancer therapeutics[17,71,73,74]. Current
technologies in pooled multiplexed library screening based on RNAi and Cas9 only
allow multiplexing of two different perturbagens. Furthermore, the size of multiplexed
libraries grows squarely as the numbers of perturbagens increase for each gene, since
for both RNAi and Cas9, multiple shRNA or sgRNA must be designed for each gene.
There is a great need for high throughput multiplexed functional genomics screenings
of higher orders of combinations as well as better pairwise multiplexed libraries with
greatly reduced library size.

14

Chapter 2: Materials and Methods
Part of this chapter is based on the article titled Pooled library screening with
multiplexed Cpf1 library (Liu J, Srinivasan S, Li C-Y, Ho I-L, Rose J, Shaheen M, Wang
G, Yao W, Deem A, Bristow C, Hart T, Draetta G. Pooled library screening with
multiplexed Cpf1 library. Nat Commun. 2019;10:3144.) was published in Nature
Communications in 2019. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY 4.0). Under Creative Commons,
authors retain copyright in their articles and I am the primary author of this article. I am
the first author of this article.

2.1 Cell culture
All cell lines were authenticated using short tandem repeat (STR) fingerprinting and
tested to be mycoplasma free by MDACC characterized cell line core facility. K-562
cells (ATCC, CCL-243) were cultured in RPMI-1640(Hyclone, SH30027.01 )
supplemented with 10% fetal bovine serum (Gibco, heat-inactivated, 10082147),
penicillin (100U/mL final concentration) and streptomycin (100U/mL). Lenti-X
293T(Clonetech) were cultured in DMEM (Hyclone, SH30243.01) supplemented with
10% fetal bovine serum (Gibco, heat-inactivated), penicillin (100U/mL final
concentration) and streptomycin (100U/mL).
2.2 Immunoblotting
For adherent cell lines, cells were trypsinized with TrypLE Express Enzyme 1x
(Gibco, 12605036), neutralized with 3x volumes of culture medium to yield a single cell
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suspension before centrifugation. All cell suspensions were centrifuged at 300g and
washed three times with Hanks’ Balanced Salt Solution. Cells were counted to ensure
identical cell numbers before lysis. For whole cell lysate, cells were directly lysed by
adding 1x Laemmli reducing buffer (Boston BioProducts, BP-111R) and mixing,
followed by three 20s sonication at 20% amplitude on ice. For the preparation of cell
fraction lysate, two protocols were used and yield identical results. The first method
was using cell fraction kit(Cell signaling technology, 9038) per the manufacturer's
protocol. For the second method, cytosol fraction lysate was acquired by lysing cell
with 0.1% NP40 containing phosphate buffered saline (PBS). The nuclear fraction
lysate was acquired treating the remaining fraction with whole cell lysate preparation
protocol. The cell lysate was heated at 95 °C for 5 minutes before SDS-PAGE. SDSPAGE was done using Mini-PROTEAN TGX precast gels (Biorad, 4561085) and
proteins were transferred to nitrocellulose membrane using the Trans-Blot Turbo
Transfer system (Biorad) with 15-minute high molecule weight protein transfer protocol.
Membranes were blocked with 5% non-fat milk at room temperature for 2 hours.
AsCpf1 antibody (Genetex, GTX133298, 1:250), Histone H3 antibody (CST,
9715,1:3000), Beta-tubulin (Sigma, T4026,1:3000) were incubated overnight at 4 °C.
Anti-rabbit (CST,7074,1:2000) and anti-mouse secondary antibody (CST,7076,1:2000)
were incubated for 3 hours at room temperature. SuperSignal West Pico PLUS
(Thermo Scientific, 34580) was used for chemiluminescent band detection.
2.3 Immunofluorescence microscopy
Before the experiment, lab-tek chamber slides were treated with 0.1% poly-lysine
solution at 37 °C for 2 hours, washed and dried at room temperature to enhance cell
attachment. HEK-293T (ATCC, CRL-3216 ) cells were seeded on lab-tek chamber
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slides and transfected with Lipofectamine 3000(Life Technologies, L3000001) per
manufacturer's protocol. At the endpoint of the assay, cells were washed once with
PBS and fixed with 4% formalin in PBS. After three washing steps with PBS, 5 minutes
each, slides were blocked with PBS supplemented with 5% normal goat serum and
0.3% Triton X-100 for 60 minutes at room temperature. Phospho-histone
H2A.X(Ser139) D7T2V mouse monoclonal antibody (CST, 80312, 1:200) was diluted in
blocking buffer and used for the primary antibody incubation at 4 ° C. Goat anti-mouse
Alexa flour488(Fisher Scientific, PIA32723,1:600) was incubated 2 hours in 3% BSA
PBS-TritonX-100 solution for the detection. Nucleus was stained with Vectashield
antifade mounting medium with DAPI.
2.4 In-cell western
The cell was seeded on poly-lysine pre-treated 96 well plates with the black wall
with method 2.3. After treatment, cells are fixed with 4% formalin in PBS. A protocol
similar to 2.3 was used for antibody incubation. Histone H2A.X(D17A3) monoclonal
rabbit antibody (CST,7631, 1:100) and phospho-histone H2A.X(Ser139) D7T2V mouse
monoclonal antibody (CST, 80312, 1:200) were mixed as a cocktail for in-cell Western
per manufacture’s standard in-cell western protocol. IRDye 800CW goat anti-mouse
IgG (LICOR,925-32210, 1:1000) and IRDye 680RD goat anti-rabbit IgG (LICOR,92568071,1:1000) were used as secondary antibodies followed by Odyssey CLx scanning
and signal was readout with Image Studio software.
2.5 T7E1 assay
72 hours post-transfection of guide and nuclease, cell genomic DNA was extracted
with Qiagen DNeasy blood and tissue kit per manufacturer's protocol. Genomic DNA
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was used for the template of PCR with NEB Onetaq mastermix (M0482S) with standard
buffer per following protocol.
Temperature
Duration
cycle
94°C
5min
94°C
30s
60°C
30s
72°C
1min
72°C
2min
4°C
Forever
Table 2 Genomic PCR thermocycler setting for T7E1 assay

1

34

The product was first denatured at 98°C for 5 minutes, then slowly annealed to
75°C at 1°C /s and eventually to 25°C at 0.1°C /s. 5U T7 Endonuclease I (NEB,
M0302S) was used for digestion of less than 300 ng annealed product for 30 minutes.
The digested product was subjected to 2% TAE agarose gel electrophoresis.
Gene
Symbol
RESP18
NEUROD
6
NAMPT
PRAMEF
2
SLC22A9
COX7B2
TFAP2D
GUCY2F
ADAM30
FNDC9

Spacer sequcence
CAGGTTGTGCTC
CAGCAGAT
ATTCATCTTGCA
TTGTGAGA
CCTCAATCCAAT
TTGTAAGC
AATGGCTCCAGA
TGAAGCGT
AGGACCTCCTG
GGTCACGCT
TGGCCAAGGGA
AACATCATG
TCCCTTCTTAGT
TCTACTTC
TTGGACCTACCA
ACCCTGGC
CTTTGGGTCGTT
TACTTTCA
GGTGCTGATGG
CCATTCTGC

Genomic PCR primer-F
TATCTGTAAGTTGGT
ACCAAGAGTGAAT
ACTCTTGATAATTCCA
AGTCCATGAAAC
TAGTGATAAATGTTCT
TAGCAGAAGCAC
TATTCCCTTTACCTTC
CACTGAGTAAAG
AGCAAATTATTTCTTA
CGTGACTTTAGAGAA
ATAGGTTCCATTCTAT
TCCAATCTGAGT
TTGCTCTGTACAAAA
ACAAACAAAAACT
CAAGTTCCTGTGGTG
CTTGTGCCTT
TAGGAAACTCACTAC
TTTCAGAGCTTTA
TATTACCATATTATGT
ACAGGCCCAACT

Genomic PCR primer-R
CTCTTCCAAGGTGTTC
TAGTGCAAATAG
ACAAAAGGAAAGGAA
AAGAAGTTCTCAT
ATTGAAGCCTGGAAA
GGTTAAGTAAATT
CCCTGGATTTGTCTTC
TAGAGATTTTTC
GATGAACAAAGCGAC
GACACTTCT
TCTGTAGAGTCAATGC
ATTGGATATTTG
CTCACAGACATTTTCA
CAAACATTGAAA
ACCCAAATGTCTTCAT
CTGAGGAAAT
AAAGCAAAAACTGAAC
AGGAAGAATCTA
ATTCCCCACAATGAGG
CAGTATAG
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ADAM18

CCTTCCTCTCTG GGGGCCTGTAGAACT AATAAGCAGCAGAAAT
AAACTTCA
GCAATGTCTAATT
GGGGGAACAAGA
ADAM18
CATCATTACAAT AGTCACCCCACACAT TGTTCTTGGGTTCAAC
TGATGGAC
TAAATTGGTCACA
GGCTTATATGCA
ADAM18
GAAATTCGGCAG CAAGCGAATACTCAC ACCCTGGATTGATTTC
CATATCCT
AGGGACTCTCTTG
ATGGGAATAGGC
ADAM18
GCAGAAAGACC
TGGCTCTTACTAATG ACTTTCCAAATATTTTA
AGCCCTACA
ATAAACTGCCCCC
GATGAAGTTTCAATGT
IL3
CAGAACGCATCA TACTCTGTAACCTTTC GAGGTTTCAGAAGTTC
GCAATTGA
CCCCTTAAGTGTA
TGCTGTTTTTGAT
IL3
AGAATGCTCTCA TACTCTGTAACCTTTC GAGGTTTCAGAAGTTC
ATTGCTGA
CCCCTTAAGTGTA
TGCTGTTTTTGAT
IL3
CACAGAATCTCC TACTCTGTAACCTTTC GAGGTTTCAGAAGTTC
TGCCATGT
CCCCTTAAGTGTA
TGCTGTTTTTGAT
IL3
TAGCGACATCCA TACTCTGTAACCTTTC GAGGTTTCAGAAGTTC
ATCCATAT
CCCCTTAAGTGTA
TGCTGTTTTTGAT
PAX4
GCTCCAAGACAC CTCCCGAGTACCTGT AGGGGAGGTGAGAAA
CTGTGCGG
GCAGAGATGATTC
TTGGAAGCAAATT
PAX4
GCTCCAGCTGTC CTCTCCACCTCATTG TCAGAGAGTCCTCAGT
CTCACTCC
GAACCCAAAG
GTGACACAGG
PAX4
CACGGGCCACT ATGGGTCTCCCCTTA ACCATGGTATTGAGCA
GAATCAGGA
GGCAACACTCC
CCCTTTCCAC
PAX4
CCACTTGAGCTT ATGCCCACATTGCCA TCGGAGGTTGAAAAG
CTCTTGCC
AATAAGAAAGGTTCT GGGAGCCTCA
VSX2
AGATTCTGAAGA GGCCTTTGCCTCTCT AGCCTTTCCTTTCTCC
TGTTTCCT
TACAACGAAATC
TGAACAAGGAG
VSX2
GATCGCTGGAG GGCCTTTGCCTCTCT AGCCTTTCCTTTCTCC
GAAACATCT
TACAACGAAATC
TGAACAAGGAG
VSX2
CCTCCTACCAGC GAATTTGTGTCCTATT ATCTGGAACCCTGGA
TAGAGGAG
GTGCTGAGCCAG
GTGGTAGATGT
VSX2
GCCCGGAGCAC AACCCGAATACCAAC TTGCCTCAGAGAGCAT
CGCAATGCT
AATTCTTTCTAGGGA
CTCCCAGCA
CTGATGGTCCAT CACAACAGCTTCATG CTGCTCGGTGAATTTG
DNMT1
GTCTGTTA
TCAGCC
GCTC
Table 3 Genomic PCR primer (5’-3’) sets for T7E1 assay of multiple genes used in this
study

2.6 Plasmid construction
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For the construction of human codon-optimized AsCpf1 were PCR amplified with
primers containing different NLS signals in NEB Q5 hot start high-fidelity master mix
from plasmid SQT1659 (Addgene# 78743) using the following parameters. LentiAsCpf1-Blast (Addgene# 84750) was digested with AgeI-HF(NEB, R3552) and BamHIHF(NEB, R3136). NLS modified AsCpf1 and digested vector were ligated using Gibson
Assembly.

Temperature
98°C
98°C
60°C
72°C
72°C
4°C

Duration
1min
10s
30s
2min
4min
Forever

cycle
1

34

Table 4 Genomic PCR thermocycler setting for cloning of different AsCpf1 variants
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Figure 1 Plasmid map of SQT1659
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Figure 2 Plasmid map of Lenti-AsCpf1-Blast

The primers were used as followed:

Primer name
hCpf11xmycNLS-F
hCpf13xmycNLS-F
hCpf12xmycNLS-F

Primer sequence
ACGGGTTTGCCGCCAGAACACAGGACCGGTGCCACCATGCC
TGCTGCCAAGAGGGTCAAGTTGGACACACAGTTCGAGGGCT
TT
ACGGGTTTGCCGCCAGAACACAGGACCGGTGCCACCATGCC
TGCTGCCAAGAGGGTCAAGTTGGACCCTGCTGCCAAGAGGG
TCAAGTTGGACCCTGCTGCCAAGAGGGTCAAGTTGGACACAC
AGTTCGAGGGCTTT
ACGGGTTTGCCGCCAGAACACAGGACCGGTGCCACCATGCC
TGCTGCCAAGAGGGTCAAGTTGGACCCTGCTGCCAAGAGGG
TCAAGTTGGACACACAGTTCGAGGGCTTT
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hCpf1-noNLSstop-R
hCpf1-mycNLSR
hCpf1-NLSstop-R
hCpf1-noNLS-R

tttcagcagagagaagtttgttgcgccggatccTCACTATTAGTTGCGCAGCT
CCTGGATGTA
tttcagcagagagaagtttgttgcgccggatccGTCCAACTTGACCCTCTTGG
CAGCAGGGTTGCGCAGCTCCTGGATGTA
tttcagcagagagaagtttgttgcgccggatccTCACTATTACTTTTTCTTTTTT
GCCTGGCCGGCC
tttcagcagagagaagtttgttgcgccggatccGTTGCGCAGCTCCTGGATGT
A
hCpf1F
acgggtttgccgccagaacacaggaACCGGTCGCCACCATGAC
hCpf1F2XNLS
acgggtttgccgccagaacacaggaCCGGTGCCACCATGCCAAAGAAG
AAGCGGAAGGTCGGTGCCCCAAAGAAGAAGCGGAAGGTCGG
T
hCpf1F3XNLS
acgggtttgccgccagaacacaggaCCGGTGCCACCATGCCAAAGAAG
AAGCGGAAGGTCGGTCCAAAGAAGAAGCGGAAGGTCGGTGC
CCCAAAGAAGAAGCGGAAGGTCGGT
hCpf1RnoHA
tttcagcagagagaagtttgttgcgccggatccGGATCCCTTTTTCTTTTTTGC
CTGGCCGG
hCpf1R
tttcagcagagagaagtttgttgcgccggatccGGCATAGTCGGGGACATCA
TATG
Table 5 Primer (5’-3’) used for generating different AsCpf1 Variants

Successfully generated variants are as followed:
Name

Reverse Primer

Variant 0

Forward
Primer
hCpf1F

Variant 1

hCpf1F

Variant 2

hCpf1F

Variant 3

hCpf1F

Variant 4
Variant 5

hCpf1F
hCpf11xmycNLS-F
hCpf12xmycNLS-F
hCpf13xmycNLS-F
hCpf11xmycNLS-F

Variant 6
Variant 7
Variant 8

Ancestor
variant
SQT1659

N-NLS

C-NLS

-

hCpf1-noNLSstop-R
hCpf1-mycNLSR
hCpf1-NLSstop-R
hCpf1-noNLS-R
hCpf1RnoHA

Variant 0

-

nucleopl
asmin
-

Variant 0

-

Variant 0

-

Variant 0
Variant 0

1xmyc

hCpf1RnoHA

Variant 0

2xmyc

hCpf1RnoHA

Variant 0

3xmyc

hCpf1-noNLS-R

Variant 0

1xmyc

hCpf1RnoHA

HAtag
-

P2ABlast
+

-

-

1xmyc

-

+

nucleopl
asmin
nucleopl
asmin
nucleopl
asmin
nucleopl
asmin
-

-

-

-

+
+

-

+

-

+

-

+
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Variant 9
AsCpf13xMYC
Variant 11
Variant 12
Variant 13

hCpf12xmycNLS-F
hCpf13xmycNLS-F
hCpf1F2XNL
S
hCpf1F3XNL
S
hCpf1F

hCpf1-noNLS-R

Variant 0

2xmyc

-

-

+

hCpf1-noNLS-R

Variant 0

3xmyc

-

-

+

hCpf1-noNLS-R

Variant 0

+

Variant 0

-

+

hCpf1R

SQT1659

nucleopl
asmin
nucleopl
asmin
nucleopl
asmin

-

hCpf1-noNLS-R

2xSV4
0
3xSV4
0
-

+

+

Table 6 Successfully constructed AsCpf1 variants

To construct LentiUniversal-Puro, site-directed point mutagenesis was used to
incorporate 2 Esp3I (BsmBI) (Life Technologies, FD0454) sites flanking Cas9’s guide
scaffold in LentiGuide-Puro using NEB Q5 site-directed mutagenesis kit (NEB,
E0554)per manufacturer's protocol. Briefly, LentiGuide-Puro was PCR amplified with
NEB Q5 Hotstart High-Fidelity 2X Master Mix (NEB, M0494S)with the following
parameters:
Temperature
Duration
cycle
98°C
1min
98°C
10s
72°C
30s
72°C
6min
72°C
12min
4°C
Forever
Table 7 Genomic PCR thermocycler setting for site-directed mutagenesis

1
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The primers used for introducing mutated sites were:
Primer
name
site1-F
site1-R

Primer sequence
ATATATCTTGTGGGGAGACGAAAGGACGAAACACCGGAGACGGTT
GTA
TCCTTTCGTCTCCCCACAAGATATATAAAGCCAAGAAATCGAAATA
CTTTCAAGTTACGGTAAGC
24

site2-F

AATTAAGGATCCCCTCGGCGTCTCTGGTTAAGCTTGGCGTAACTAG
ATCTTGAGACAA
site2-R
AACCAGAGACGCCGAGGGGATCCTTAATTAAAAAAGCACCGACTC
GGTGCCA
Table 8 Primers (5’-3’) used for site-directed mutagenesis

Figure 3 Plasmid map of constructed LentiUniversal-Puro
To construct individual mono-cistronic and multiplexed AsCpf1 guide or guide
arrays, 1µg LentiUniversal-Puro were digested with 1µl Esp3I (Thermo Scientific) and
1µl FastAP Thermosensitive Alkaline Phosphatase(EF0654) in 20µL reaction for 2
hours at 37 °C and the 8kb backbone fragment was purified by 0.8% agarose gel
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electrophoresis. For mono-cistronic guides, oligos were first phosphorylated with T4
PNK at 37 °C for 30 minutes and annealed with protocol mentioned in T7E1 assay.
Name
ADAM18-1

ADAM18-2

ADAM18-3

ADAM18-4

IL3-1

IL3-2

IL3-3

IL3-4

PAX4-1

PAX4-2

Forward oligo
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATCC
TTCCTCTCTGAAACTTCATTTT
TT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATCA
TCATTACAATTGATGGACTTTT
TT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATGA
AATTCGGCAGCATATCCTTTTT
TT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATGC
AGAAAGACCAGCCCTACATTT
TTT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATCA
GAACGCATCAGCAATTGATTT
TTT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATAG
AATGCTCTCAATTGCTGATTTT
TT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATCA
CAGAATCTCCTGCCATGTTTTT
TT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATTA
GCGACATCCAATCCATATTTTT
TT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATGC
TCCAAGACACCTGTGCGGTTT
TTT
GTGGAAAGGACGAAACACCG
TAATTTCTACTCTTGTAGATGC
TCCAGCTGTCCTCACTCCTTT
TTT

Reverse oligo
AACCAAAAAATGAAGTTTCAGA
GAGGAAGGATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
AACCAAAAAAGTCCATCAATTGT
AATGATGATCTACAAGAGTAGA
AATTACGGTGTTTCGTCCTTT
AACCAAAAAAAGGATATGCTGC
CGAATTTCATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
AACCAAAAAATGTAGGGCTGGT
CTTTCTGCATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
AACCAAAAAATCAATTGCTGATG
CGTTCTGATCTACAAGAGTAGA
AATTACGGTGTTTCGTCCTTT
AACCAAAAAATCAGCAATTGAG
AGCATTCTATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
AACCAAAAAAACATGGCAGGAG
ATTCTGTGATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
AACCAAAAAAATATGGATTGGAT
GTCGCTAATCTACAAGAGTAGA
AATTACGGTGTTTCGTCCTTT
AACCAAAAAACCGCACAGGTGT
CTTGGAGCATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
AACCAAAAAAGGAGTGAGGACA
GCTGGAGCATCTACAAGAGTAG
AAATTACGGTGTTTCGTCCTTT
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PAX4-3

GTGGAAAGGACGAAACACCG AACCAAAAAATCCTGATTCAGT
TAATTTCTACTCTTGTAGATCA GGCCCGTGATCTACAAGAGTAG
CGGGCCACTGAATCAGGATTT AAATTACGGTGTTTCGTCCTTT
TTT
PAX4-4
GTGGAAAGGACGAAACACCG AACCAAAAAAGGCAAGAGAAGC
TAATTTCTACTCTTGTAGATCC TCAAGTGGATCTACAAGAGTAG
ACTTGAGCTTCTCTTGCCTTTT AAATTACGGTGTTTCGTCCTTT
TT
VSX2-1
GTGGAAAGGACGAAACACCG AACCAAAAAAAGGAAACATCTT
TAATTTCTACTCTTGTAGATAG CAGAATCTATCTACAAGAGTAG
ATTCTGAAGATGTTTCCTTTTT AAATTACGGTGTTTCGTCCTTT
TT
VSX2-2
GTGGAAAGGACGAAACACCG AACCAAAAAAAGATGTTTCCTCC
TAATTTCTACTCTTGTAGATGA AGCGATCATCTACAAGAGTAGA
TCGCTGGAGGAAACATCTTTT AATTACGGTGTTTCGTCCTTT
TTT
VSX2-3
GTGGAAAGGACGAAACACCG AACCAAAAAACTCCTCTAGCTG
TAATTTCTACTCTTGTAGATCC GTAGGAGGATCTACAAGAGTAG
TCCTACCAGCTAGAGGAGTTT AAATTACGGTGTTTCGTCCTTT
TTT
VSX2-4
GTGGAAAGGACGAAACACCG AACCAAAAAAAGCATTGCGGTG
TAATTTCTACTCTTGTAGATGC CTCCGGGCATCTACAAGAGTAG
CCGGAGCACCGCAATGCTTTT AAATTACGGTGTTTCGTCCTTT
TTT
Table 9 Primers(5’-3’) used for generating AsCpf1 mono-cistronic guides targeting
non-essential genes

For multiplexed guide arrays, synthesized array templates were PCR amplified with
NEB Q5 Hotstart High-Fidelity 2X Master Mix, and digested with Esp3I and purified with
Zymo DNA clean and concentrator (D4013).
Gene name
ADAM18

IL3

Template
AAAGGACGAAACACCGTAATTTCTACTCTTGTAGATCCTTCCTCTC
TGAAACTTCATAATTTCTACTCTTGTAGATCATCATTACAATTGATG
GACTAATTTCTACTCTTGTAGATGAAATTCGGCAGCATATCCTTAA
TTTCTACTCTTGTAGATGCAGAAAGACCAGCCCTACATTTTTTGGT
TGGAGACGCGAT
AAAGGACGAAACACCGTAATTTCTACTCTTGTAGATCAGAACGCA
TCAGCAATTGATAATTTCTACTCTTGTAGATAGAATGCTCTCAATT
GCTGATAATTTCTACTCTTGTAGATCACAGAATCTCCTGCCATGTT
27

AATTTCTACTCTTGTAGATTAGCGACATCCAATCCATATTTTTTTGG
TTGGAGACGCGAT
PAX4
AAAGGACGAAACACCGTAATTTCTACTCTTGTAGATGCTCCAAGA
CACCTGTGCGGTAATTTCTACTCTTGTAGATGCTCCAGCTGTCCT
CACTCCTAATTTCTACTCTTGTAGATCACGGGCCACTGAATCAGG
ATAATTTCTACTCTTGTAGATCCACTTGAGCTTCTCTTGCCTTTTTT
GGTTGGAGACGCGAT
VSX2
AAAGGACGAAACACCGTAATTTCTACTCTTGTAGATAGATTCTGAA
GATGTTTCCTTAATTTCTACTCTTGTAGATGATCGCTGGAGGAAAC
ATCTTAATTTCTACTCTTGTAGATCCTCCTACCAGCTAGAGGAGTA
ATTTCTACTCTTGTAGATGCCCGGAGCACCGCAATGCTTTTTTTG
GTTGGAGACGCGAT
Table 10 Sequences (5’-3’) of multiplexed AsCpf1 array templates
The PCR conditions are as followed

Forward primer ATCGCGTCTCTGTGGAAAGGACGAAACACCG
Reverse primer ATCGCGTCTCCAACC
Temperature
Duration
cycle
98°C
1min
1
98°C
10s
60°C
20s
72°C
2min
20
72°C
4min
4°C
Forever
Table 11 Genomic PCR thermocycler setting for cloning of multiplexed AsCpf1 guide
arrays

Both inserts and backbone are quantified with Nanodrop 2000 and NEB Fastligation Kit
was used to ligate them together. The molar ratio of insert and backbone was 10:1.
2.7 Plasmid transfection
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Cells were cultured to a ~80% confluency and transfected with Lipofectamine
3000(Thermo scientific, L3000001) or 1µg/µL 25kD linear polyethyleneimine(PEI)
(Polysciences, 23966-1) per manufacturer’s protocol at the following dose according to
the surface of the culture vessel. The ratio of the plasmid (µg): P3000 reagent (µL):
Lipofectamine 3000 (µL) was 1:2:2. The ratio of the plasmid (µg): PEI(µL) was 1:5.
Vessel
96-well (1 48-well (1 24-well (1 12-well (1
type
well)
well)
well)
well)
DNA
67ng
200ng
400ng
800ng
amount
Vessel
10cm
75cm2
175cm2
225cm2
type
dish
flask
flask
flask
DNA
12µg
16µg
37µg
47µg
amount
Table 12 Plasmid dosage used for transfections

25cm2
flask
5µg

6-well (1
well)
2µg

2cm
dish
2µg

15cm
dish
32µg

500cm2 assay
plate
105µg

2.8 Benchmark library design
A total number of 342 core-essential genes and 345 non-essential genes were
used to generate both Cas9 and AsCpf1 based libraries, with 3 guides per gene.
Design of guides was accomplished by program CLD[75]. On-target selection rules
were identical for both Cas9 and AsCpf1 except for the different requirements of PAM.
For each transcript that a guide target, “NGG” PAM was used for Cas9 and “TTTV” was
used for AsCpf1, where “V” can be any nucleotide other than “T”. Guides targeting the
most transcripts, closest to the first exon and with minimum predicted off-targets were
prioritized. Briefly, all possible guides were designed for each gene and then filtered
with Bowtie for “off-target” prediction. Mismatch tolerance of Cas9 was set to be up to 2
mismatches across 20bp spacer and up to 1 mismatch across PAM adjacent 18bp for
AsCpf1. Any guides having over 2 predicted off-target sites across human genome
hg19 or targeting regions documented in dbSNP were excluded. Next, each remaining
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guides were scored according to the numbers of transcripts they are targeting and the
proximity to the protein start codon. Each guide was assigned a score of zero before
calculation. For each start codon and transcript it hits, 1 is added. Top three scored
guides were selected for each gene.1911 out of 2061 guides were predicted to be offtarget free in Cas9 library and 1899 out of 2061 guides were in AsCpf1 library.
2.9 Genome-wide library design
Guides were identified by adapting the Cas9 library design algorithm developed by
Hart et.al [61]. Candidate guide sequences were obtained from exonic regions using
hg38 and are filtered for homopolymers and BsmBI restriction sites. Using Bowtie, we
aligned the filtered candidate guides across the genome, allowing for one mismatch
outside the “TTTV” PAM sequence. Guides with off-target matches in intronic or exonic
regions were excluded, and the remaining guides were ranked based on the number of
off-target matches in intergenic regions. A sequence score as the sum of individual
nucleotide’s score was assigned to each guide based on the score table below. The top
four guides that have minimum off-target matches and highest scores were selected. In
the case of fewer than four guides were available, three guides were selected. Genes
that have less than three available guides were not included in the library. All guides
targeting the same gene were concatenated and interspaced with AsCpf1’s guide
scaffold sequence “TAATTTCTACTCTTGTAGAT” in a tandem fashion.
Nucleotide position
A
C
G
T

1
-0.1418
0.6899
0.6039
-1.152

2
0.1356
0.6451
-0.159
-0.6217

3
0.1815
-0.8305
0.0521
0.5969

4
-0.2616
0.0684
0.5141
-0.3209

5
-0.5439
0.1034
0.6818
-0.2413

Nucleotide position

6

7

8

9

10
30

A
C
G
T

0.4031
-0.2562
0.1811
-0.328

-0.256
0.6877
0.0493
-0.481

-0.1082
-0.1222
0.2835
-0.0532

0.0219
0.3201
-0.3546
0.0125

0.3984
0.2787
-0.4432
-0.2338

Nucleotide position
A
C
G
T

11
0.4617
0.0908
-0.7986
0.2461

12
0.4188
-0.0187
-0.4274
0.0274

13
0.2653
0.1303
-0.1264
-0.2692

14
0.5542
-0.3212
-0.0894
-0.1436

15
0.3864
-0.223
0.0776
-0.241

Nucleotide position
16
17
18
A
-0.2017
0.4938
0.0838
C
0.0935
-0.3918
0.1221
G
-0.5581
-0.4441
-0.9018
T
0.6662
0.342
0.6959
Table 13 Guide scoring matrix of AsCpf1 based guide

19
-0.1502
0.4049
-0.3065
0.0519

20
0.701
-0.4567
-0.2329
-0.0113

To ensure the identical length of guide arrays consisting of either three or four
guides, a randomly selected 20bp non-targeting stuffer sequence was used as a
surrogate guide. The stuffer sequences used are listed below.
Sequence
Sequence
GAGATTGGGCGTTTACTCGG
GACGCCTTGACCGGTCTGCA
GATACGCTCTCGCCCTTCCC
GATTGTGGTCTCATCGGGCG
GGTCAGGTTACGGTCAGATC
GACCTGATGGCCGAGATTAA
GTAACGCGCTTGGGTCAAGC
GTATCAATAGCAAGCGTCGC
GTCTAACCGAACAATACGAC
GCTCGCGCGCGCTAAAGACT
GTAGTCTCCTTGGTAATCGA
GACGCTGTTCGCGCTTCGAA
GTCCCTAGCTGAAGGACCGG
GGTCGTTTAACGGACCTATG
GGTTCGGATGTCGTCGTCCC
GTATCAGTCCGCCGCTGTTA
GCAGCGGTCGGTCAACTTAT
GGCAAACTTCGCTAGGCGAT
GCAACGCGGTGGCGTAACGT
GTCAAGCCGAACTTGTTAGC
Table 14 Sequences (5’-3’) of non-targeting suffers in genome-wide AsCpf1
multiplexed library
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To generate the oligo sequences for the genome-wide library, the length unified
quadruple AsCpf1 guide arrays were attached a 5’ adaptor sequence
“AAAGGACGAAACACCG” and 3’ adaptor sequence
“TTTTTTGGTTGGAGACGCGAT”.
2.10

Library construction

10µg LentiUniversal-Puro were digested with 5µl Esp3I (Thermo Scientific) and 5µl
FastAP Thermosensitive Alkaline Phosphatase in 100 µL reaction for 2 hours at 37 °C
and the 8kb backbone fragment was purified by 0.8% agarose gel electrophoresis. The
oligo libraries were synthesized by Twist Biosciences. To generate the library inserts,
oligo libraries were first suspended at a concentration of 1µg/µL and used for PCR
amplification with the following conditions:
Component
Volume µL
NEBNext® Q5® Hot Start HiFi PCR Master Mix
Water
Primer1 (100µM)
Primer2 (100µM)
ET SSB
Oligo library
Table 15 PCR reaction setup for amplification of oligo pools

Temperature
Duration
cycle
98°C
1min
98°C
10s
60°C(AsCpf1 library) ,64°C(Cas9 library) 30s
72°C
2min
72°C
4min
4°C
Forever
Table 16 Genomic PCR thermocycler setting for amplification of oligo pools

50
44
0.5
0.5
1
4

1
8
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Primers for AsCpf1 based library were
“ATCGCGTCTCTGTGGAAAGGACGAAACACCG” and “ATCGCGTCTCCAACC”.
Primers for Cas9 based library were
“GGCTTTATATATCTTGTGGAAAGGACGAAACACCG” and
“CTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC”. PCR products were gel
purified with Zymo Gel DNA Recovery Kit and quantified with Nanodrop2000. Gibson
Assembly was used to clone Cas9 based library into the backbone. For AsCpf1
libraries, PCR products were digested with Esp3I and cloned into the same backbone
with Quickligase ligation kit (NEB) at an insert: backbone ratio of 10:1. DH10B MegaX
(Life technologies) electroporation competent cells were used for transformation per
manufacturer’s protocol. Eight transformations were done for each library. For each
transformation, 100ng DNA was used. Transformed cells were plated on 100 µg/mL
carbenicillin containing LB agar assay plates and cultured for 16 hours at 30 °C.
Colonies were enumerated via counting diluted transformants plated on an agar plate.
Plasmid extraction of bacteria library was only performed when colonies on assay plate
were estimated to exceed 100-fold coverage of library complexity.

2.11

Lentiviral library packaging and titering

Lenti-X 293T(Clonetech) were transfected with plasmid the library,
PMD2.G(Addgene #12259), PsPAX2 (Addgene #12260) to generate the lentiviral
libraries. Briefly, Lenti-X 293T were seeded and grew to 90% confluency in two T-175
cell culture flasks.29 μg plasmid library, 30 μg PsPAX2 and 8.8 μg PMD2.G were
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transfected with Lipofectamine3000 for each flask. 16 hours after the transfection, the
medium was replaced with 4 mM caffeine containing DMEM with 10% FBS. 48 hours
post medium change, the cell culture medium was collected and centrifuged at 1500 g
for 10 minutes. The supernatant was aliquoted and stored at -80 °C.
Viruses were defrosted at room temperature and distributed in 6-well plate from 1
μL at a log2 increase. After the distribution of lentivirus, K-562 culture containing 1x105
cells and 8 μg/ml polybrene was added to each well. Puromycin was added to the
culture 24 hours later to reach a final concentration of 2 μg/ml. Cells in each well were
quantified using CellTiter-Glo luminescence cell viability assay (Promega). Linear
regression between cell numbers and virus volume was done only for data points within
the linear range. The data point that has the highest viability was set to be the
reference point and the cells in that data point were considered 100% infected. The
virus’s titer was calculated based on the regression formula and reference data point.
2.12

Pooled library screening

K-562 cell line was infected with each library at <0.3 multiplicity of infection at
aimed coverage of at least 1000-fold. 48 hours post infection, the cell culture medium
was changed into cell culture medium containing 2 μg/ml puromycin. 4 days postinfection, cells were infected with lentivirus generated from lentiCas9-Blast (Addgene
#52962) and lentiAsCpf1-3xMYC correspondingly, ~1000X infected cells were isolated
for each library for reference purpose. 6 days from the first infection, cells were further
selected with 10 μg/ml blasticidin and split into triplicates for each group. Regular
sampling was taken during the process of screening at each time point, cells were
pelleted and frozen at -80 °C before further processing. At each sampling and screen
process, cells were maintained at a minimum of 1000-fold complexity of the libraries
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per replicate. For the genome-wide Mini-human library screening in K562, we used
500x coverage.

2.13

Preparation of next-generation sequencing

Genomic DNA was extracted from cell pellets using DNAzol (MRC Inc.) per
manufacturer’s protocol. ¼ of the total amount of DNA for each sample was used for
genomic PCR. Multiplexing barcodes and Illumina sequencing adaptors were
incorporated in the 1-step PCR with NEBNext Q5 Hot Start HiFi PCR Master Mix with
following conditions: initial denaturing at 98°C for 1 min, denaturing at 98°C for 10s,
annealing at 64°C for 20s, elongation at 72°C for 30s, final elongation for 2 min. PCR
cycles for each sample were controlled to the minimal level where the target bands
could be seen in 2% agarose TAE gel to ensure unbiased PCR amplification. The
primers were used as followed.
The forward primer containing P5 Illumina adaptor is an equal molar mixture of 8
staggered primers
Sequence
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTTTGTGGAAAGGACGAAACACCG
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTCTTGTGGAAAGGACGAAACACCG
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTGCTTGTGGAAAGGACGAAACACCG
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTAGCTTGTGGAAAGGACGAAACACCG
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTCAACTTGTGGAAAGGACGAAACACCG
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTTGCACCTTGTGGAAAGGACGAAACACCG
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTACGCAACTTGTGGAAAGGACGAAACACCG
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AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCTGAAGACCCTTGTGGAAAGGACGAAACACCG
Table 17 Primer (5’-3’) sequences of P5 primers for genomic PCR from cell pellets
derived from library screenings
Each sample has a different reverse primer that only differs in an 8-digit barcode:
CAAGCAGAAGACGGCATACGAGATCGGTTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCTGGATTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAACTCGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAACAGTTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATACTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCTGAGAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATTGGAGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAGTCTAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGGTGACCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTACAGAGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATTGTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTATGTCTTGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATTGGATTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATACTCGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTATGAGAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCACAGTTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGTGGATTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAGTAGAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCACGATTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
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CAAGCAGAAGACGGCATACGAGATCGGTAGCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAGTTCTTGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTACAAGTTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATCACTGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGCATCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAACTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGTGAGCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATCAGAGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTATGGAGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCGTTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGCAAGAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGACAGCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGACTCGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTACAAGAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGCAGATTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATTGCTCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCACTCGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATGTTCTTGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATATGTCTCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCACTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTAGTAGCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGTGTCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCGTTCTTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
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CAAGCAGAAGACGGCATACGAGATGCCAAGCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCACCTCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCACCTGGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATGCCAGACCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATCGCAAGCCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
CAAGCAGAAGACGGCATACGAGATTACATCAAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT
Table 18 Primer (5’-3’) sequences of P5 primers for genomic PCR from cell pellets
derived from library screenings
Target bands were excised from the gel and purified with Freeze 'N Squeeze™
DNA Gel Extraction Spin Columns (Bio-rad), quantified by Qubit dsDNA HS Assay kit
per manufacturer’s guidance and pooled together. The pooled Illumina library was then
subjected to Nextseq550 high output sequencing.

2.14

NGS data processing and analysis

Reads were demultiplexed with bcl2fastq software at a zero base mismatch
tolerance of barcode. After demultiplexing, reads were trimmed with cutadapt v1.8 and
FASTX-Toolkit to remove adaptor sequences and guide scaffold sequences, leaving
only protospacer information. The trimmed sequences are mapped with reference by
Bowtie with 1 base mismatch allowed and the mapped reads counts were extracted
with samtools and used for further bioinformatics analysis.
All quality control and fold change calculation were done with customized R scripts.
Lowfat BAGEL developed by Sanjana Srinivasan was used for hits calling and
generation of precision and recall curves. The BAGEL computational framework
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estimates the distributions for the core essential and non-essential genes by
bootstrapping the reference genes across 1000 permutations – where roughly 60% of
the genes are randomly selected as a “training set”, and Bayes Factors (BF) for the
remaining genes belonging to the “testing set” is calculated. The final BF for each gene
is the average of the Bayes factors obtained in the 1000 permutations. This method,
while extremely robust in whole-genome screens, results in overfitting of small library
screens such as the benchmark screens we conducted as we are limited to 342
essential and 345 non-essential genes. To address this, we utilized a modified version
of BAGEL suited for small libraries, termed Low Fat BAGEL. Rather than focusing on
gene level BFs, we leveraged all available data by treating each sgRNA, for each gene,
as an independent data point. Similar to BAGEL, 100 permutations are performed on
the individual guides of the reference set, rather than on the level of each gene. The
500 guides are bootstrapped across 100 permutations, and the resulting BF for each
guide computed is an average of all permutations. An aggregate BF for each gene is
then obtained by summing the BFs of individual guides.
We quantified the performance of library screenings with a modified Area Under
the precision-recall Curve(AUC) parameter called mAUC. To calculate the mAUC, the
AUC of a null distribution of a non-functional screening is subtracted from the AUC of a
given screening. A screen is not functional when it cannot distinguish essential gene
targeting guides versus non-essential gene guides. At any given recall rate, the
precision rate (true positive/all positive) should be a constant (i.e. the likelihood of an
unknown guide X being an essential gene targeting guide, which is 342/ (342+345)
=0.498). Therefore, for a null distribution, the AUC is 0.498. Lopes et.al for the detailed
mathematical proof. [76]
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Chapter 3: Multiplexed pooled library with AsCpf1
This chapter is based on the article titled Pooled library screening with
multiplexed Cpf1 library (Liu J, Srinivasan S, Li C-Y, Ho I-L, Rose J, Shaheen M, Wang
G, Yao W, Deem A, Bristow C, Hart T, Draetta G. Pooled library screening with
multiplexed Cpf1 library. Nat Commun. 2019;10:3144.) was published in Nature
Communications in 2019. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY 4.0). Under Creative Commons,
authors retain copyright in their articles and I am the primary author of this article. I am
the first author of this article.

3.1

Introduction
Based on its inherent properties, including short guide length and autonomous

guide processing activity, we inferred that the CRISPR/Cpf1 system may enable
multiplexed libraries compatible with pooled library screenings. The system would
eliminate the need for a trade-off between library efficacy and library complexity by
multiplexing of different guides targeting the same gene into a single lentiviral vector.
However, even though Cpf1 is active in mammalian cells, multiple groups have
reported diminished efficiency compared with SpCas9[44,77,78], and whether Cpf1
offers an adequate solution for the purpose of functional genomes screening remains
unknown.
3.2

Design and construction of benchmark libraries
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To assess the performance of Cpf1 multiplexing, we generated a multiplexed
AsCpf1 library targeting 342 “core-essential” genes and 345 “non-essential” genes, with
three guides per gene[58,61] (2061 guides, 687 constructs). Fitness changes upon
knockout of these genes are highly consistent across multiple cell lines, therefore
making them “gold-standard” controls. To compare the screening performance of the
multiplexed AsCpf1 library and conventional mono-cistronic CRISPR knock out
libraries, we generated two additional benchmark CRISPR libraries targeting the same
group of genes: an SpCas9-based mono-cistronic library (2061 guides, 2061
constructs) and an AsCpf1-based mono-cistronic library (2061 guides, 2061
constructs). The design rules for SpCas9 and AsCpf1 guides are highly similar, despite
nuclease-specific requirements, such as different protospacer adjacent motifs. The
AsCpf1-based mono-cistronic and multiplexed libraries shared identical guide
sequences; however, the multiplexed AsCpf1 library had only a single construct
harboring all three guides (Figure 4).

Figure 4 SpCas9 and AsCpf1 based guide libraries.
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In SpCas9 or AsCpf1 based mono-cistronic libraries, the basic unit is an SpCas9
or AsCpf1 guide, targeting one gene. Each gene has multiple guides dispersed in
different lentivirus. In AsCpf1 based multiplexed library, the basic unit is an AsCpf1
guide array driven by one polymerase III promoters (e.g. human U6), targeting one
gene. Each gene only has one corresponding guide array construct. However, each
array contains multiple different guides targeting one gene.

We noted extensive rearrangements between the multiplexed AsCpf1 guide
arrays when using Gibson assembly to clone synthesized oligo pools into the
backbone. The rearrangements included loss of guides and random shuffling of guides.
(Figure 5a, b,c ).
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Figure 5 Examples of amplicon rearrangement caused by Gibson assembly
Rearranged molecule generated from 2 different 3-guide array amplicon,
resulting 4-guide hybrid (a), 3-guide hybrid (b), and truncated 2-guide hybrid(c).

This phenomenon was independent of the polymerases used in the PCR
reaction as well as the bacteria host strains (Figure 6).
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Figure 6 Rate of amplicon rearrangement using different cloning methods, DNA
polymerase, and bacteria strain

However, the rearrangements were not observed when we employed classical
restriction enzyme-based cloning, suggesting that the identical sequence of AsCpf1
scaffolds might have led to incorrect recombination during Gibson assembly (Figure 7).
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Figure 7 Two proposed amplicon rearrangement caused by the Gibson assembly.
After PCR, amplicons of oligo duplexes are added into Gibson assembly reaction
(step 1), T5 exonuclease starts to erode the duplexes from both strands’ 5’ terminals,
exposing the direct repeat sequence of AsCpf1 guides as single strand ready for
hybridization (step 2). Different guide arrays hybrid together because of homology in
guides’ direct repeats, leaving a long imperfect tail. Phusion polymerase binds to the
tails and uses its 3’ to 5’ exonuclease activity to degrade the tails until it meets the
perfect hybridization regions consisting of guide direct repeats (step3). Taq polymerase
seals nicks between the hybrid chains (step 4) and the recombined molecule is
generated and cloned into a vector (step 5).
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3.3

Optimization of AsCpf1 for functional genomics screening
For these benchmark screens, we employed K-562 cells separately infected with

each pooled CRISPR library at a low multiplicity of infection (MOI). After puromycin
selection, we delivered the corresponding CRISPR nuclease (AsCpf1 or SpCas9) by
lentivirus transduction and blasticidin selection. We conducted triplicate screens with
cells grown for 4 weeks and sampled each replica at intermediate time points to
capture the dynamics of guide populations. We measured screen performance by the
relative differential fold change of “core-essential” vs “non-essential” genes (Figure 8).

Figure 8 Pooled library screen pipeline schematics.
K-562 were firstly infected with guide libraries (i.e. SpCas9 based mon-cistronic,
AsCpf1 based mono-cistronic and AsCpf1 based multiplexed library) separately at low
multiplicity of infection (<0.3) to ensure most infected cells were infected by one
lentivirus. Two days post-infection, cells were selected with puromycin. After the noninfected cells were wiped out, a reference sample for all three libraries was collected
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and frozen for the following next-generation sequencing. The remaining cells were split
into triplicates for each library and infected with lentivirus containing their corresponding
CRISPR nuclease (i.e. for SpCas9 based library, SpCas9 nuclease was used. For
AsCpf1 based libraries, AsCpf1 was used.). Cells were then selected with blasticidin to
ensure SpCas9 and AsCpf1 were integrated and then screened in blasticidin and
puromycin containing culture medium for 4 weeks. Samples were taken from each
replicate every week to capture the screen dynamics.

Somewhat unexpectedly, the common AsCpf1 variant used (human codonoptimized AsCpf1 with a C-terminal nucleoplasmin bi-partite nucleus localization signal
(NLS), herein AsCpf1-Nuc)[38], [79] failed to show satisfactory separation of essential
vs non-essential genes in the screen (Figure 9a), despite showing activity when tested
by T7E1 assay with individual constructs from the libraries (Figure 9b).
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Figure 9 Activity of AsCpf1-Nuc and AsCpf1-3xMYC variants
a. Log2 transformed guide fold change plot of AsCpf1-nuc variant and AsCpf13xMYC based screen. The AsCpf1-nuc variant based screen was conducted at the
same controlled conditions with AsCpf1-3xMYC. Pink dot: the mean value of log2
transformed fold change of essential gene targeting guides at the endpoint. Purple dot:
the mean value of log2 transformed fold change of non-essential gene targeting guides
at the endpoint. b. T7E1 assay of 10 different loci transfected with AsCpf1-nuc and
corresponding guides. HEK293-T cells were transfected with AsCpf1-Nuc and guides in
complexed with lipofectamine 3000. T7E1 assay was performed 72 hours post
infection. Active guides are indicated by “*”. Upper panel: cells transfected with AsCpf1nuc and guide. Lower panel: cells transfected with guides only. Lane1 to lane 10: T7E1
assay products targeting loci (from left to right) RESP18, NEUROD6, NAMPT,
PRAMEF2, SLC22A9, COX7B2, TFAP2D, GUCY2F, ADAM30, and FNDC9. P: T7E1
assay product of DNMT1 edited allele as a positive control for T7 endonuclease
activity. E: Empty lane. M: NEB 100bp DNA ladder.
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We hypothesized that this might be caused by inefficient AsCpf1 nuclear
translocation. To test this hypothesis, we evaluated library performance with one of
several AsCpf1 variants carrying different NLSs. We found that an AsCpf1 bearing Nterminal 3x MYC-NLS and an optimized Kozak sequence (herein AsCpf1-3xMYC)
effectively discriminated positive and negative control genes in our benchmark library
screens (Figure 10a). Moreover, when cells were infected by AsCpf1-3xMYC or Aspf1Nuc at identical MOI, AsCpf1-3xMYC showed stronger expression and nuclear
localization compared to AsCpf1-Nuc, (Figure 10b).

Figure 10 Performance of AsCpf1-3xMYC
a. Log2 transformed guide fold change plot of AsCpf1-3xMYC and SpCas9
based screen. Pink dot: the mean value of log2 transformed fold change of essential
gene targeting guides at the endpoint. Purple dot: the mean value of log2 transformed
fold change of non-essential gene targeting guides at the endpoint. b. Western blot of
AsCpf1 variant. K-562 cells were infected with AsCpf1-Nuc (the commonly used
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variant) and AsCpf1-3xMYC (Kozak sequence and nucleus localization signal
optimized variant) virus at the same multiplicity of infection. After blasticidin selection,
lysates of different cellular fraction were subjected to western blot. Beta-tubulin was the
whole cell extract loading control and Histone H3 was the nucleus fraction lysate
loading control. The AsCpf1-3xMYC variant showed stronger expression and nucleus
localization.
Using the T7E1 assay, we also confirmed a much higher editing efficiency for
this variant compared to AsCpf1-Nuc (Figure 11), suggesting that the amount of
AsCpf1 in the nuclear fraction is critical for optimal gene editing efficiency.

Figure 11 T7E1 assay results of AsCpf1 variants on locus DNMT1
HEK293-T cells were transfected with different AsCpf1 variants and guide
targeting DNMT1 locus (lane 1-3) in complex with lipofectamine 3000. T7E1 assay was
performed 72 hours post infection. Lane 4: negative control with guide transfection
only. Lane M: NEB 100bp DNA ladder

3.4

Functional genomics screening with benchmark libraries
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We then repeated the benchmark screens with AsCpf1-3xMYC. All biological
replicates for each of the three library screens were well correlated, indicating good

Cas9_Reference Point

1

Cas9Replicate3_Time Point4

Cas9Replicate3_Time Point3

Cas9Replicate3_Time Point2

Cas9Replicate3_Time Point1

Cas9Replicate2_Time Point4

Cas9Replicate2_Time Point3

Cas9Replicate2_Time Point2

Cas9Replicate2_Time Point1

Cas9Replicate1_Time Point4

Cas9Replicate1_Time Point3

Cas9Replicate1_Time Point2

Cas9Replicate1_Time Point1

Cas9_Reference Point

reproducibility (Figure 12,13,14).

0.64 0.49 0.41 0.29 0.64 0.47 0.39 0.27 0.56 0.47 0.39 0.27
0.92 0.82 0.62 0.96 0.88 0.78 0.6 0.9 0.88 0.78 0.61

0.9

0.95 0.79 0.88 0.93 0.88 0.73 0.83 0.93 0.88 0.73

0.8

Cas9Replicate1_Time Point1

0.64

Cas9Replicate1_Time Point2

0.49 0.92

Cas9Replicate1_Time Point3

0.41 0.82 0.95

Cas9Replicate1_Time Point4

0.29 0.62 0.79 0.91

Cas9Replicate2_Time Point1

0.64 0.96 0.88 0.79 0.6

Cas9Replicate2_Time Point2

0.47 0.88 0.93 0.88 0.72 0.91

Cas9Replicate2_Time Point3

0.39 0.78 0.88 0.88 0.79 0.8 0.95

Cas9Replicate2_Time Point4

0.27 0.6 0.73 0.79 0.8 0.62 0.79 0.91

Cas9Replicate3_Time Point1

0.56 0.9 0.83 0.74 0.56 0.9 0.83 0.73 0.56

Cas9Replicate3_Time Point2

0.47 0.88 0.93 0.87 0.72 0.88 0.92 0.87 0.73 0.85

Cas9Replicate3_Time Point3

0.39 0.78 0.88 0.88 0.78 0.78 0.87 0.88 0.79 0.75 0.95

Cas9Replicate3_Time Point4

0.27 0.61 0.73 0.79 0.8 0.6 0.73 0.79 0.81 0.58 0.8 0.92

1

1

1

1

0.91 0.79 0.88 0.88 0.79 0.74 0.87 0.88 0.79
1

0.6 0.72 0.79 0.8 0.56 0.72 0.78 0.8
1

0.91 0.8 0.62 0.9 0.88 0.78 0.6
1

0.95 0.79 0.83 0.92 0.87 0.73
1

0.91 0.73 0.87 0.88 0.79
1

0.56 0.73 0.79 0.81
1

0.85 0.75 0.58
1

0.95 0.8
1

0.92
1

0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

Figure 12 Pearson correlation coefficient matrices of all samples for SpCas9 based
monocistronic library screening
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Figure 13 Pearson correlation coefficient matrices of all samples for AsCpf1 based
monocistronic library screening
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Figure 14 Pearson correlation coefficient matrices of all samples for AsCpf1 based
multiplexed library screening
An essential gene-targeting construct was considered active if it was more
depleted compared to a non-essential gene targeting construct since it should have an
anti-proliferative effect if active. To determine the percentages of active constructs
among the three different libraries, we chose a false positive rate (FPR) of 5% based
on the log2 transformed fold change for each time point. The active construct
percentage curve of the SpCas9-based mono-cistronic library was relatively flat across
all four time points, with a mean value of 49.0% ± 2.9% active constructs. For AsCpf1based libraries, the active construct percentage curve plateaued 2 weeks after the
screen initiated with mean values of 31.7% ± 0.9% and 77.4% ± 1.4% active constructs
for the monocistronic and multiplexed libraries, respectively (Figure 15a). The different
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shapes of the active construct percentage curves for SpCas9- and AsCpf1-based
screens indicate different population temporal dynamics and knockout efficiency for the
different CRISPR nucleases. Our data suggest that SpCas9 is more active in
mammalian cell gene knockout experiments compared to AsCpf1, consistent with prior
reports[44,77,78]. However, multiplexing different guides targeting the same gene
significantly increased the likelihood of gene knockout with AsCpf1. At endpoint, the
percentage of active constructs in the AsCpf1 multiplexed library was only slightly
increased compared to other libraries when we relaxed the FPR stringency from 5% to
20% (increased by 4.4% ± 1.9% at 10% FPR and 9.9% ± 0.8% at 20%FPR) (Figure
15b), highlighting the high signal-to-noise ratio of the multiplexed AsCpf1 screen.

Figure 15 Performance comparison between Cas9 and AsCpf1 based libraries
a. The percentage of the active construct for different libraries at the 5% false
positive rate across 4 time points. Data is based on log2 transformed fold change. Pink:
Cas9 based mono-cistronic CRISPR library. Yellow: AsCpf1 based mono-cistronic
CRISPR library. Purple: AsCpf1 based multiplexed CRISPR library. Error bars are
present as SD.b. The increased percentage of the active construct for different libraries
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at the screen endpoint with a different controlled false positive rate. Data is based on
log2 transformed fold change. Pink: Cas9 based mono-cistronic CRISPR library.
Yellow: AsCpf1 based mono-cistronic CRISPR library. Purple: AsCpf1 based
multiplexed CRISPR library Error bars are present as SD.

To call out significantly depleted genes, we used an adapted Bayesian Analysis
of Gene Essentiality (BAGEL) algorithm to analyze construct-level data. On the basis of
the fold change in sgRNA abundance after knockout of each gene in the essential and
non-essential training sets, BAGEL uses a Bayesian model selection approach to
classify a Bayes Factor (BF), which is the log2 likelihood of each gene belonging to
either the essential gene distribution or non-essential gene distribution. Because
BAGEL is designed for whole-genome CRISPR screens, we designed and utilized a
version of BAGEL optimized for small library screens, “Low Fat BAGEL”. Low Fat
BAGEL generates BFs on a construct-level basis that is summed across guides to
obtain a gene-level BF. For the AsCpf1-based multiplexed library, each gene has only
one corresponding construct; therefore, its construct-level BF corresponds directly to its
gene-level BF.
To benchmark screen performance across the three libraries, precision-recall
curves were plotted based on BFs. The precision-recall curves clearly showed that the
SpCas9-based mono-cistronic screen (construct-wise area under the curve (AUC) 0.78
± 0.01, gene-wise AUC 0.89 ± 0.01) outperformed the AsCpf1-based mono-cistronic
screen (construct-wise AUC 0.70 ± 0.01, gene-wise AUC 0.82 ± 0.01) at both the
construct (Figure 16a) and the gene level (Figure 16b). However, the AsCpf1-based
multiplexed screen (construct-wise and gene-wise AUC 0.89 ± 0.00) performed
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similarly to the SpCas9 monocistronic library at the gene level, and it yielded a much
stronger performance at the construct level, primarily due to lower active construct
percentage in the SpCas9 screen.

Figure 16 Precision-recall curves for different CRISPR libraries
a. The construct-level precision-recall curves for CRISPR libraries. The
construct-level precision-recall curves are based on the Bayes factor ranks for each
guide at the endpoint. Each curve represents one biological replicate. Pink: Cas9
based mono-cistronic CRISPR library. Purple: AsCpf1 based multiplexed CRISPR
library. Yellow: AsCpf1 based mono-cistronic CRISPR library.b. The gene-level
precision-recall curves for CRISPR libraries. The gene-level precision-recall curves are
based on the sum of Bayes factor ranks for all guides of the same gene at the
endpoint. Each curve represents one biological replicate. Pink: Cas9 based monocistronic CRISPR library. Purple: AsCpf1 based multiplexed CRISPR library. Yellow:
AsCpf1 based mono-cistronic CRISPR library.
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To compare the separation rate between essential and non-essential genes
among the three library screens, we calculated the ratio of the modified area under the
precision-recall curve (mAUC) of any given time point divided by the mAUC at endpoint
(ratio of mAUC, rmAUC) (Figure 17).
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Figure 17 The rmAUC curves of CRISPR libraries describing population dynamics.
rmAUC (ratio of the modified area under the curve) is calculated by (AUCx0.498)/(AUCend-0.498) x 100%. AUCx: the area under the curve of construct-wise
precision-recall curves for time point X. AUCend: the area under the curve of constructwise precision-recall curves of the endpoint. Pink: Cas9 based mono-cistronic CRISPR
library. Yellow: AsCpf1 based mono-cistronic CRISPR library. Purple: AsCpf1 based
multiplexed CRISPR library. Error bars are present as SD

As the area under the precision-recall curve (AUC) for this library would be
0.498 when there is no separation between essential and non-essential genes, the
mAUC for any given time point was set to be its AUC minus 0.498. As shown in Figure
17, the results suggest that separation between essential and non-essential genes in
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the AsCpf1-based mono-cistronic screens was much slower compared to SpCas9based mono-cistronic and AsCpf1-based multiplexed screens. This might be the result
of the relatively slower cleavage dynamics of AsCpf1 compared with SpCas9[41], as
we also saw a slightly slower separation between essential genes and non-essential
genes in the AsCpf1 based multiplexed screen compared with SpCas9 indicating the
slower separation is not unique to the mono-cistronic AsCpf1 library.
Overall, the multiplexed AsCpf1 and SpCas9 libraries performed comparably,
while the monocistronic AsCpf1 library was inferior to both. To compare the
performance at the individual gene level, we performed a gene-matched Wilcoxon test
based on the rank of essential genes across the three libraries. We failed to find
statistically significant differences (p=0.2409 for Cas9 vs Cpf1 mono-cistronic,
p=0.2142 for Cas9 vs Cpf1 multiplexed), indicating that Cas9- and Cpf1-based libraries
performed similarly at the individual gene level. We also performed Spearman’s
correlation analysis on the z-score of essential genes, and found significant correlations
between Cas9- and Cpf1-based libraries (Spearman’s Rho = 0.48, p=2x10-40 for Cas9
vs Cpf1 mono-cistronic; Spearman’s Rho = 0.57, p=2x10-61 for Cas9 vs Cpf1
multiplexed), again demonstrating similarly high performance of Cas9- and Cpf1-based
libraries (Figure 18).
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Figure 18 Correlation analysis of benchmark libraries.
Z scores of the essential gene from each library were used.
3.5

Optimization of AsCpf1’s guide design with benchmark library screening

data
CRISPR/SpCas9 guide design has been optimized using empirical data from
hundreds of screens[50,51,54,61], but previous AsCpf1 guide optimization algorithms
were largely based on a small number of surrogate reporter experiments[79]. It is
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known that lentiviruses have integration site biases[80] and that the chromosomal
environment can influence CRISPR nuclease activity[81]. Thus, the gene editing
process on surrogate reporters might not fully represent the true biological effects on
endogenous loci editing. Our screen provides a large-scale action-in-situ dataset to
enable prediction of AsCpf1 guide preference based on functional screening data of
endogenous loci. We used fold change information of essential gene-targeting guides
in the mono-cistronic AsCpf1 library to calculate sequence preference, as effective
guides should drop out more efficiently than ineffective ones. Even though all of the
342 genes are considered essential genes, the severity of their knockout phenotypes
may differ. To avoid sequence biases introduced by gene-specific effects, within the
three guides in each gene, we classified the most depleted guide as the “highperforming” guide and the least depleted guide as the “low-performing” guide. Using a
scoring scheme similar to that described by Hart et al.[61], we calculated the frequency
of each nucleotide at each position of the 20-mer protospacer individually for highperforming and low-performing guides. At each position, the nucleotide frequency of
low-performing guide was subtracted from the high-performing guide to produce a table
with subtracted frequencies for each nucleotide. This process was repeated across 100
bootstraps, and an aggregate average score table for each protospacer position was
obtained. In agreement with a previous report[79], thymine (T) was strongly disfavored
in position 1 in the protospacer, while guanine (G) and cytosine (C) were favored. We
also identified features not previously reported. For example, we found a general trend
of G disfavor from position 16 to position 20 in the protospacers. In addition, we found
that T was favored in positions 3,16, and 18, while C was favored in position 7 but
disfavored in position 3 (Figure 19).
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Figure 19 The scoring matrix for the prediction of AsCpf1 activity on endogenous loci.
The screen data of mono-cistronic AsCpf1 library was used to generate the heat
map of nucleotide preferences on protospacers. A positive value (in red tone) indicates
a preference towards a nucleotide for a high performing guide while negative value (in
blue tone) indicates a preference against a high performing guide. The position of the
first nucleotide adjacent to PAM is defined as position 1 for the protospacer.

These features are previously unidentified by surrogate reporters and are not
biases from selecting the core-essential gene guides as the training dataset, as there is
no significant correlation between guide scores and depletion level for non-essential
genes (Spearman’s rho=-0.01, p=0.65) (Figure 20).
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Figure 20 Correlation plot of activity scores and log2 transformed fold change of nonessential gene targeting guides. (Spearman’s rho=-0.01, p=0.65)

The score table obtained served as a metric to predict guide activity in terms of
fold change: the indicated sequence score for each guide represented the sum of the
nucleotide score at each position. Therefore, a guide with a zero-sequence score
indicates no similarity between either effective or non-effective guides. We validated
our prediction algorithm on the “median-performing” guides not used to develop the
scoring algorithm – that is, the guide for each gene that was neither the highest nor
lowest performing guide. Each median-performing guide was assigned a sequence
score and was classified with a prediction of “high-performing” or “low-performing”
based on a guide score > 0 or ≤ 0, respectively. We then evaluated if the sequence
score and predicted performance classification of each guide were indicative of fold
change and found a significant correlation between the guide score and guide
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performance (Spearman’s rho = -0.40, 95% confidence interval: (-0.34, -0.45), p=4.5 x
10-40) (Figure 21a). The predicted high-performing guides were significantly more
effective than low-performing guides, with a mean log2 fold change of -3.19 compared
to -1.16 (t = -10.13, p = 4.9 x 10-23) (Figure 21b).

Figure 21 Correlations between guide score and log2 transformed fold changes
a. Correlation between AsCpf1 guide prediction scores and Log2 transformed
fold change. The predicted AsCpf1 guide scores for each validation guides across 100
bootstrappings were plotted against their log2 transformed fold change in the screen.
(n=342) b. Log2 transformed fold change of 100 bootstrapped prediction of high
performing AsCpf1 guides and low performing guides. Guides were defined as high
performing if predicting score > 0 and low performing if predicting score ≤ 0. (n=342)
Error bars are present as SD.
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3.6

Genome-wide functional genomics screening with AsCpf1 based

multiplexed library Mini-human
Based on our multiplexed AsCpf1 library strategy, we designed and constructed
the smallest available CRISPR library targeting the entire human protein-coding
genome, “Mini-human”. The guides for Mini-human were optimized based on activity
scores derived from our screen dataset and further filtered for potential off-target
effects. Because a previous analysis of published screens determined that for SpCas9,
four to six gRNAs per gene yield robust results when computational approaches to
design sequence-optimized guides are employed[50,54,61], each construct in Minihuman contained up to 4 gene-targeting guides: 16393 gene-targeting constructs with
4 optimized guides, 584 gene-targeting constructs containing 3 optimized guides, and
55 non-targeting guide arrays as negative controls. This library was approximately onefourth the size of the smallest currently available genome-wide CRISPR library and will
be made publicly available.
We conducted a genome-wide screen using the Mini-human library (17,032
constructs) in K-562, a chronic myelogenous leukemia cell line, using conditions similar
to other published screenings in this model using the GeCKOv2 (123,411 constructs)
and the gold standard Wang library (the Sabatini dataset; 187,536 constructs). At the
pathway level, GSEA analysis identified common pathways related to cell survival and
replication depleted across all three datasets, including those related to the
spliceosome, ribosome, and DNA replication (Figure 22, 23, 24).
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Figure 22 Top 20 depleted KEGG pathways using GSEA with Wang library
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Figure 23 Top 20 depleted KEGG pathways using GSEA with GeCKO V2 library
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Figure 24 Top 20 depleted KEGG pathways using GSEA with Mini-human library
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To compare the datasets at the level of hits, we conducted a BAGEL analysis
with a cutoff threshold for hit identification set to a false discovery rate (FDR) of 0.01. A
similar number of hits was identified by Mini-human and Wang library, followed by
GeCKOv2 and the overlap percentages of hits between any two libraries was similar for
all hits sets and core-essential gene hits sets (Figure 25a,25b) and, in accordance
with recent reports, each library identified unique hits[82]. We performed gene ontology
enrichment analysis for dataset specific hits, which failed to identify any significantly
enriched pathways. Taken together, our results support that SpCas9 and AsCpf1
libraries induced similar cell proliferative behaviors and both are suitable for functional
genomics applications.

Figure 25 Overlap and concordance rate among different K562 genome-wide library
screen datasets.
69

a. All hits identified by different libraries b. Core-essential gene hits identified by
different libraries FDR threshold: 0.01

Next, we used the gene-level BF generated precision-recall curves to enable a
comparison of overall library performance. We determined that the Sabatini dataset
outperformed both datasets, and Mini-human outperformed GeCKOv2 AUC =0.98,
AUC =0.96, and AUC =0.94, respectively) (Figure 26a). The number of guides per
gene differs among all three libraries: Mini-human has 3 to 4 guides per gene on a
single construct, whereas the GeCKOv2 and Wang libraries use 6 or 10 monocistronic
guides per gene, respectively. The Wang library employed an optimized guide design
strategy, and even after down-sampling (average of 10 random down-samplings with 4
guides per gene), it still outperformed the other libraries (Figure 26b). Overall, the
libraries performed similarly in the K-562 functional screening, indicating that a
multiplexed AsCpf1 library can yield robust results comparable with commonly used
SpCas9 based mono-cistronic libraries in this context.
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Figure 26 Gene-level precision-recall curves for genome-wide CRISPR libraries.
a. precision-recall curves using full-size libraries. b. precision-recall curves using
down-sampled Wang library and full-size GeCKOv2 and Mini-human libraries Red:
GeCKOv2 library. Yellow: Mini-human library. Blue: Wang library.
3.7

Genotoxicity with AsCpf1 based multiplexed genome editing
Multiple groups have reported copy number-related genotoxicity in SpCas9-

based pooled library screenings wherein highly amplified genes showed reduced
fitness regardless of their biological function. In the multiplexed AsCpf1 library, each
lentivirus particle is capable of introducing multiple double-strand breaks (DSBs) into a
single locus. We characterized the distance between cuts generated by our benchmark
multiplexed AsCpf1 library. Over 90% of the multiplexed AsCpf1 guides spanning a
genomic distance <10 kb (Figure 27), which is smaller than the scale of common copy
number amplifications.
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Figure 27 Frequency distribution of the maximum distance among double-strand
breaks generated by constructs in benchmark AsCpf1 multiplexed library

To investigate whether these on-target DSBs may similarly diminish fitness, we
randomly selected four non-essential genes (ADAM18, IL3, PAX4, and VSX2) and
compared their multiplexed AsCpf1 constructs from Mini-human with corresponding
monocistronic guide vectors transfected with an AsCpf1-expressing plasmid. 14 out of
the 16 monocistronic guides were confirmed to be active as indicated by T7E1
assay(Figure 28).
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Figure 28 T7E1 assay results of AsCpf1 on non-essential gene loci.
HEK293-T cells were transfected with AsCpf1-3xMYC and guides in complexed
with lipofectamine 3000. T7E1 assay was performed 72 hours post infection. Active
guides are indicated by “*”. Upper panel: cells transfected with AsCpf1-3xMYC and
guide. Lower panel: cells transfected with guides only. T7E1 assay products targeting
loci (from left to right): ADAM, IL3, PAX4, VSX2. For each locus, 4 guides were
selected from Mini-human library. Ladder: NEB 100bp DNA ladder.

Analysis of cell viability via CCK-8 assay identified no difference between cells
infected with multiplexed versus monocistronic vectors (Figure 30a). Furthermore,
H2A.X phosphorylation levels measured by In-cell Western analysis were similar
between the two groups, whereas a control culture of cells treated with 100 nM
gemcitabine for one hour accumulated phosphorylated H2A.X, as expected (Figure
30b). The antibody used for In-cell Western analysis were validated by
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immunofluorescence microscopy using gemcitabine (a DNA damaging reagent) treated
and non-treated cells(Figure 29).

Figure 29 Immunofluorescence microscopy validation of p-H2A.X antibody used for incell Western.
HEK293-T cells were transfected with AsCpf1-3xMYC and empty guide vector in
complexed with Lipofectamine 3000 (Transfection control) or treated with 1-hour
100nM gemcitabine incubation (+Gemcitabine) and stained for H2A.X phosphorylation
and nucleus.
Finally, quantification of Annexin-V was similar between cells harboring
multiplexed or monocistronic vectors (Figure 30c). Thus, the multiplexed guide vectors
in Mini-human do not negatively impact cell viability or induce accumulation of DNA
damage or apoptosis compared to monocistronic guide vectors, and our data indicate
that the deleterious effects of copy number-related, locus-independent cutting by
SpCas9 are not recapitulated in AsCpf1-based multiplexed systems.
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Figure 30 Toxicity characterization of multiplexed AsCpf1 arrays and monocistronic
vectors
a. Relative viability of cells treated by AsCpf1 and different single-guide vectors
or multiplexed guide vectors. b. Phosphorylation H2A.X signal of cells treated by
AsCpf1 and different single-guide vectors or multiplexed guide vectors. Gemcitabine:1hour 100nM gemcitabine treatment prior to In-cell Western assay as a positive control.
c. Annexin V staining signal of cells treated by AsCpf1 and different single-guide
vectors or multiplexed guide vectors. Error bars are present as SD
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3.8

Discussions and future directions
We provide evidence to support the deployment of a multiplexed, AsCpf1-based

system for functional genomics applications. In accordance with previous reports, we
found that, in general, AsCpf1 underperforms SpCas9 in terms of activity, and we found
that AsCpf1 performance correlated with its nuclear localization. However, we
demonstrate a significant improvement in AsCpf1-based library performance when
guides were multiplexed into a single vector. We thus created a library that combines
AsCpf1-3xMYC, a variant with optimized nuclear localization and cutting, with
multiplexed guide vectors, and demonstrated that it performed similarly to conventional
SpCas9 libraries. Our experiments provide proof of principle supporting the utility of
multiplexed AsCpf1-based libraries to address a critical need in functional genomics for
highly efficient pooled libraries with low complexity.
It is not clear why multiplexing guides enhances the performance of AsCpf1based libraries. One likely contributing factor is that the probability of generating an ontarget loss-of-function mutation is increased, because of better sampling of an effective
guide from the multiplexed vector, thereby reducing the screening analysis noise
introduced by nonfunctional constructs. It is also possible that, by introducing more
than one cut on a single locus, the multiplexed library may increase the chances of a
functional deletion. Specifically, the multiple cuts may delete a larger nucleotide
sequence compared with the indels that are the dominant repair product at a single
endonuclease cleavage site. Consistent with this idea are reports that that bi-cistronic
SpCas9 guides can generate fragment deletions[67].
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We used our benchmark mono-cistronic AsCpf1 screening dataset to generate
preference rules for designing guides for AsCpf1. This is the first dataset available to
mine for AsCpf1 guide preference on endogenous loci and may reveal chromatin
features that are not detected by surrogate reporters. Our data are consistent with
previous reports that uridine in the first spacer nucleotide position (thymine in the first
protospacer position) has a strong, negative effect on guide performance. We also
uncovered previously unappreciated preferences for guanine and cytosine at specific
positions. Whether these features are cell-specific or if they are affected by chromatin
configuration remain interesting points for future investigation.
No obvious locus-independent cytotoxic effect was identified for the multiplexed
AsCpf1 guide vectors. The high signal-to-noise ratio of the multiplexed library indicated
there is no interference in the pooled library screen using the multiplexed guide
strategy. Biochemical assays using several non-essential gene vectors also confirmed
no additional cytotoxicity caused by multiplexing. This was in contrast with the reported
on-target cytotoxic effect of SpCas9 targeting high copy number regions. This could be
explained by differential sensitivity to DSBs of different cell lines, or it is feasible that
four DSBs are not sufficient to trigger locus-independent cytotoxicity. Another possible
explanation is that the genomic distances between DSBs introduced by multiplexed
AsCpf1 vectors are different compared to SpCas9-induced DSBs that have been
shown to exert a copy number-related cytotoxic effect. In scenarios where guides span
larger distances, one potential approach to mitigate concerns about DSB-induced
toxicity is to sample early time points for a reference population, as copy number
effects are reported to appear early in the screening process or apply scoring
algorithms such as CERES[56] to take the copy number effect into consideration. The
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amplification of off-target effects by multiplexed vectors can be addressed by selecting
guides that are predicted to be low off-targeting or off-target free, which is feasible for
AsCpf1 and LbCpf1, for which off-target properties have been extensively
studied[38,44]. Moreover, the higher fidelity of Cpf1 compared with SpCas9 contributes
to mitigating the increased risk of off-target effects introduced by multiplexing.
We constructed the first multiplexed genome-wide CRISPR knock out library,
Mini-human, which represents a new, powerful tool for demanding functional genomics
applications, especially in vivo pooled library screenings where library size is a
concern. Using K-562 cells as a model system, we demonstrated that Mini-human
performs similarly well compared with conventional SpCas9-based libraries such as
GeCKOv2 and the Wang library. The superior performance of the Wang library can be
attributed to its much larger number of guides per gene (10 guides per gene vs 6 for
GeCKOv2 and 3 to 4 for Mini-human) and the high coverage used in the screening
(1000x vs 500x for GeCKOv2 and Mini-human). These data suggest that increasing
guide number within the multiplexed vector may also be beneficial in the context of
AsCpf1-based multiplexed libraries. Current oligo pool synthesis technologies enable
multiplexing of up to 7 guides, with the upper limit resulting from technical factors
surrounding the synthesis of oligo pools. With a carefully designed cloning strategy, a
larger number of multiplexed guides may be attainable.
For AsCpf1, the number of guides available for each gene can sometimes be
limiting for library construction. AsCpf1 has a strict requirement for the TTTV PAM
motif, resulting in a smaller selection of guides available compared with SpCas9, which
requires NGG or NAG PAM. Multiple AsCpf1 variants have been identified that can
target non-canonical PAMs such as TYCV, TATV, TTYN, VTTV, and TRTV. Using
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these variants instead of wild type could increase the guide selection pool for AsCpf1based libraries; however, it is unknown whether the variants’ protospacer nucleotide
preferences and off-target properties may vary versus wild type. It was reported[43]
that there is no position effect when AsCpf1 guide arrays were individually tested. In
the context of a pooled library screening, expression of the guide array will be more
vulnerable to various cellular machinery since only one copy of array expression
cassette will be found in most infected cells. Determining whether a guide’s efficiency is
influenced by its cistron position in a pooled library screening will be important to further
optimize AsCpf1 multiplexed library strategies.
It is reasonable to assume that a combinatorial gene knockout/down screen is
feasible using multiplexed Cpf1 guide vectors. High-throughput screening (HTS) for
multi-gene perturbation effects could greatly facilitate functional interaction studies,
such as identifying synthetic lethality to position cancer therapeutics. Previous efforts to
develop HTS systems have been based primarily on RNAi and SpCas9. While,
theoretically, RNAi can be multiplexed, it has inferior precision compared with SpCas9.
Moreover, multiple pairs of shRNA or SpCas9 expression cassettes must be tested
independently to determine the effect of perturbing a gene pair to differentiate from offtarget effects. For SpCas9, a maximum of 2 guides can be multiplexed into an
expression cassette if direct sequencing of guide spacers is desired. Furthermore,
paired SpCas9-based screenings suffer from unwanted recombination from vector
constructions and sequencing library preparations from PCR. By contrast, AsCpf1
guides are shorter, and AsCpf1 possesses autonomous guide processing capabilities
that enable a single, multiplexed vector to deliver constructs targeting multiple genes.
This approach greatly reduces library complexity. As an example, to probe all random
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two-gene combinations of 1,000 genes using 6 perturbagens (guides or shRNAs) per
gene, SpCas9 and RNAi would require a 36 million-vector library. In stark contrast, a
multiplexed AsCpf1 library would require only 1 million vectors. Furthermore, because
AsCpf1 libraries can use 300 bp, pair-end sequencing to multiplex up to 13 guides,
AsCpf1 libraries could enable multi-gene (>2) interactions to be probed. This opens up
new, systems-level HTS applications for multiplexed libraries, such as identifying
transcription factor combinations that induce stem cell differentiation.
In summary, we demonstrated feasibility for developing multiplexed AsCpf1
libraries for functional genomics applications. This approach performed comparably
compared to commonly used mono-cistronic SpCas9 libraries. A human genome-wide
minimized library, Mini-human, was developed based on this strategy and will be
available to the research community.
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